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ABSTRACT
This dissertation is dedicated to the research and investigation of novel enzymes and the
methods used to study them, with physiological roles ranging from isoprenoid biosynthesis to
neurotransmitter production. Using a combination of bioinformatics, recombinant cloning,
enzymology, and proteomics, we have contributed to the understanding and exploration of
several human illnesses, including malaria, cancer, and endocrine dysfunction.
Our first project involved studying the enzymes responsible for N-acylarylalkylamide
biosynthesis in Bombyx mori. Very little is known how these potent signaling molecules are
produced in vivo, however, one possible pathway is the direct conjugation of an acyl-CoA to a
corresponding arylalkylamide by the enzyme arylalkylamine N-acyltransferase (AANAT). In
insects, this enzyme is responsible for controlling melanism, the inactivation of biogenic amines,
the sclerotization of the insect cuticle, photoperiodism, and the penultimate intermediate in the
production of melatonin. We studied a pair of AANAT enzymes from B. mori: Bm-AANAT and
Bm-AANAT3. The former was found to catalyze the direct formation of long-chain
acylarylalkylamines (only the second enzyme discovered to do such chemistry), while the latter
exhibited potent inactivation of several amines through acetylation. We conducted a full kinetic
characterization of Bm-AANAT3, including double-reciprocal plots, pH-rate profiling, dead-end
inhibition, and the construction of mutants to elucidate catalytically-relevant amino acids. Our
hope is that new insights and discoveries on these enzymatic pathways in model organisms will
yield novel molecular targets for human health and disease.
x

We then developed an innovative, microwave-assisted synthesis of a binding-based probe
capable of enriching proteins that bind adenine ribose derivatives (AdoRs). We employed this
probe in activity-based protein profiling studies to qualitatively assess the AdoR-binding
proteome in three bacterial cell lines from the genus Bacillus. This proof of concept experiment
demonstrated a unique subset of proteins distinctive to each species, and confirmed the efficacy
of the probe tagging and subsequent enrichment. This technology can be used in clinical
applications for the detection and identification of cancerous biomarkers.
Finally, we successfully truncated and recombinantly-expressed 1-deoxy-D-xylulose-5phosphate synthase (DXS) from both P. vivax and P. falciparum. We elucidated the order of
substrate binding for both of these TPP-dependent enzymes using steady-state kinetic analyses,
dead-end inhibition, and intrinsic tryptophan fluorescence titrations. Both enzymes adhere to a
random sequential mechanism with respect to binding of both substrates: pyruvate and Dglyceraldehyde-3-phosphate. These findings are in contrast to other TPP-dependent enzymes,
which exhibit classical ordered and/or ping-pong kinetic mechanisms. A better understanding of
the kinetic mechanism for these two Plasmodial enzymes could aid in the development of novel
DXS-specific inhibitors that might prove useful in treatment of malaria.

xi

CHAPTER ONE:
INTRODUCTION

1.1 An Introduction to Fatty Acid Amides
Ironically, the birth of fatty acid amide research originated from studies pertaining to an
illegal plant, cannabis. Cannabis has been cultivated by a multitude of civilizations spanning
several millennia, where it has been used for medicine, textiles, recreation, religious rituals, and
even food.[1] However, at the turn of the century, access to the plant was limited through federal
regulations, and became fully criminalized in 1970 under the Comprehensive Drug Abuse
Prevention and Control Act.[2] The medicinal use of cannabis sharply declined as alternatives
were discovered, such as morphine and aspirin.[3] However, as the stigma of the drug has faded
in recent years, renewed interest in cannabis has fostered novel research endeavors for
therapeutic and clinical applications.[4] At current (2015), 23 states and Washington D.C. have
legalized cannabis for medical purposes, two states (Colorado and Washington) have fully
legalized its use for recreational purposes, and seven more states have pending legislation
regarding its deregulation.
The first psychoactive component of cannabis to be isolated and elucidated was (-)-Δ9tetrahydrocannabinol (or more commonly known as “THC”) by the Mechoulam group in 1964
(Figure 1.1A).[5] It was not until 1988 that the Howlett group discovered the mammalian brain
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Figure 1.1 The molecular structures of (A.) Δ9-tetrahydrocannabinol and (B.) Anandamide.

receptor for THC, the cannabinoid receptor 1 (CB1),[6] followed by the cannabinoid receptor 2
(CB2) in 1993.[7] After the identification of these receptors, it was predicted that an endogenous
ligand must exist in the mammalian brain. Shortly thereafter, the first CB1 ligand, anandamide
(or N-arachidonoylethanolamine, Figure 1.1B), was discovered from porcine brain. This
discovery ushered in a new era of studying endocannabinoids and fatty acid amides as potent
cell-signaling molecules. Anandamide is implicated in a variety of biophysical phenomena in
mammals including memory, sleep, locomotion, pain perception, body temperature regulation,
and appetite.[8-10] These physiological processes occur when anandamide binds to the CB1 and
CB2 receptors, as well as the transient receptor potential vanilloid type I (TRPV1) receptors.[11]
The biosynthetic pathway of this compound has been extensively studied; yet, for all we have
learned about anandamide, it only comprises ~10% of the long-chain N-acylethanolamines found
in the brain (which is only one type of fatty acid amide among dozens!).[12] As greater numbers
of these long-chain fatty acid amides were discovered, they were subsequently classified into
different families: primary fatty acids, N-acyl amino acids, N-acylglycines, N-acylethanolamines,
N-acylarylalkylamides, N-monoacylpolyamides, and N-acyltaurines. Examples of these
compounds are detailed in Table 1.1, while Figure 1.2 shows the general structure of fatty acid
2

amides. The focus of this dissertation will be the study of the N-acylarylalkylamides, which are
further discussed in sections 1.2 and 1.3.

Figure 1.2 General structure of fatty acid amides.

Table 1.1 Examples of each fatty acid amide family.a,b

Fatty Acid Amide Family

Structure

Primary fatty acid amides

N-acyl amino acidsc

N-acylglycines

N-acylethanolamines

N-acylarylalkylamidesd
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N-monoacylpolyamidese

N-acyltaurines
a

R1 represents alkyl groups of varying lengths, depicted in red.
Biogenic amines are colored blue, and are conjugated to the acyl group through an amide bond.
c
R2 constitutes various side chains of amino acids
d
The N-acylarylalkylamide depicted is N-acyltryptamine
e
The N-monoacylpolyamide shown is N-acylcadaverine
b

At present, most fatty acid amides have no defined neurological function, their
biosynthetic pathways have not been entirely elucidated, and the majority of their receptors
remain undiscovered.[12] Many speculate these molecules must serve some biological function,
since the brain invests substantial amounts of energy into their production.[13] Significant
research remains to identify all of the biologically feasible fatty acid amides, and to elucidate
their biosynthetic pathways. Our lab continues to vigorously add to these discoveries, with the
recent identification of various long-chain N-acylarylalkylamides in D. melanogaster (including
N-acyldopamines and N-acylserotonins),[14] which is surprising since it is suggested no
cannabinoid receptors exist in fruit flies.[15]
In addition to the discovery of these various metabolites, our lab has sought to investigate
a number of enzymes possibly implicated in the generation of fatty acid amides.[16-18] Two
potential pathways are commonly attributed to the biosynthesis of the long-chain Nacylarylalkylamides in vivo, the first being the direct condensation of a fatty acid to a biogenic
amine by fatty acid amide hydrolase, or FAAH (also known as oleamide hydrolase and
anandamide amidohydrolase; see Figure 1.3A).
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Figure 1.3. Proposed biosynthetic enzymes in the production of long-chain Nacylarylalkylamides. (A.) Fatty acid amide hydrolase (B.) N-acyltransferase

This enzyme is a member of the serine hydrolase family, and displays both esterase and amidase
activity.[19-20] Evidence of this pathway was evaluated by the Walker group for FAAH’s role in
N-arachidonoyldopamine biosynthesis.[21] In this study, a FAAH inhibitor was fed to FAAH
knockout rats while the level N-arachidonoyldopamine and anandamide were evaluated;
anandamide was selected because it is a known FAAH substrate that is hydrolyzed to
ethanolamine and arachidonic acid. When compared to control rats, the levels of anandamide
increased while levels of N-arachidonoyldopamine decreased, which suggests Narachidonoyldopamine biosynthesis is directly correlated to FAAH activity. It was theorized that
FAAH functions to either (a) directly catalyze the condensation of dopamine and arachidonic
acid to N-arachidonoyldopamine, or (b) participates in the liberation of arachidonic acid by
hydrolysis of anandamide which is then shuttled into different pathways such as Nacylarylalkylamide biosynthesis.[21] As a follow up, the researchers then evaluated recombinant
FAAH to determine whether it is a biosynthetic or degenerative enzyme for the production of N5

arachidonoyldopamine. They incubated FAAH with anandamide and deuterated dopamine, and
assayed the evolution of deuterated N-arachidonoyldopamine over 30 minutes. Their theory was
FAAH would first catalyze the hydrolysis of anandamide to arachidonic acid, which would then
subsequently serve as a substrate for the condensation with dopamine to form the Narachidonoyldopamine.[21] What they discovered was that N-arachidonoyldopamine biosynthesis
was 180-fold less than the Vmax of the FAAH catalyzed hydrolysis of anandamide; thus,
arachidonic acid and dopamine are poor substrates for a possible FAAH-catalyzed condensation
reaction. FAAH is unlikely the biosynthetic enzyme of this pathway since several of the longchain N-acylarylalkylamides (primarily the N-acylserotonins) function as inhibitors to its
enzyme-catalyzed hydrolysis reaction.[22] A more likely scenario is that FAAH functions to
degrade and liberate fatty acids, which are then utilized in other fatty acid amide biosynthetic
pathways.
The second proposed pathway of N-acylarylalkylamide biosynthesis involves the direct
acylation of a biogenic amine through an activated fatty acid (in the form of an acyl-CoA),
facilitated by an N-acyltransferase (NAT) enzyme (Figure 1.3B). This pathway is more
thermodynamically favorable over the FAAH-catalyzed reaction, since a thioester is more
susceptible to nucleophilic attack by a neutral amine. Such a reaction has been well
characterized for the N-acetylation of serotonin in the penultimate step of melatonin
biosynthesis, catalyzed by arylalkylamine N-acetyltransferase (AANAT; also commonly referred
to as serotonin N-acetyltransferase, or SNAT).[23-28] Since FAAH is a poor candidate for
catalyzing this reaction, it is thought that a group of unidentified AANAT or AANATL enzymes
with specificity for long-chain acyl-CoA substrates could be the biosynthetic enzyme for the
production of long-chain N-acylarylalkylamides. The Hunt group recently identified a NAT
6

enzyme, glycine N-acyltransferase 2 (GLYATL2), which catalyzes the formation of long-chain
N-acylglycines in vitro.[29] In addition, Dempsey et al, have demonstrated that an AANAT from
D. melanogaster is capable of producing long-chain N-acylserotonins from long-chain acyl-CoA
substrates.[16] The focus of Chapter 2 of this dissertation pertains to the study of a pair of
AANAT enzymes from Bombyx mori, one of which shows evidence of catalyzing the formation
of long-chain N-acyltryptamines, among other biogenic amines. Additional research is required
to confirm or exclude this chemical step in the biosynthesis of other long-chain Nacylarylalkylamides.

1.2 Historical Perspectives of Arylalkamine N-acetyltransferase
Arylalkamine N-acetyltransferase (AANAT) has been exhaustively studied in vertebrates
due to its role as the penultimate enzyme in the biosynthetic pathway of melatonin production.
[23-28]

In particular, this enzyme has key implications in daily and seasonal timing for metabolic

activity and developmental modifications, thus its moniker as the “timezyme.” Locations of
AANAT expression constitute the pineal gland, retina, the photosensitive parietal eyes, and the
Harderian gland of tetrapods.[30] The gastrointestinal tract of mammals may also prove to be a
site of expression due to massive amounts of melatonin detected, with nearly 400 times the
concentration as compared to the pineal gland.[31] Melatonin is involved in a litany of
physiological processes including circadian entrainment, immune function, blood pressure
regulation, oncogenesis, as well as controlling motility, inflammation, and pain in the
gastrointestinal tract. [32-33]
AANAT belongs to the GCN5-related N-acetyltransferase (GNAT) superfamily,[34] and
can be classified as either vertebrate (vt) AANAT or non-vertebrate (nv) AANAT based on
7

homology similarities. According to sequence approximations, AANATs have been identified in
Gram-positive bacteria, certain lower plants, algae, fungi, annelida, placosoa, cephalochordates,
and vertebrates; however, other published genomes are devoid of this class of enzyme, including
nematodes and higher plants.[35] Hypotheses abound that a horizontal gene transfer from bacteria
to an ancestor of vertebrates caused the evolution of this class of enzyme, since the homologs in
bacteria, green algae, and fungi lack regulatory sequences found in vtAANAT (as well as lacking
introns).[36] It is also thought that the emergence of the vtAANAT timezyme greatly accelerated
evolution, aiding substantially in reproductive success.
Since this enzyme is responsible for major neurotransmitter metabolism, it acts as an
extensive regulator in a multitude of physiological functions, developmental phases, metabolism,
behavior, and reproduction. Higher vertebrates possess one gene for AANAT, however, multiple
known acetylases function as xenobiotic enzymes: seven in cephalochordates and three in
humans.[37-38] AANAT transfers an acetyl moiety to 5-hydroxytryptamine (serotonin) and
controls periodic alterations of circulating melatonin in boney vertebrates (Figure 1.4).[39]

Figure 1.4 The synthesis of melatonin from serotonin, wherein AANAT is the penultimate
enzyme in the pathway.
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In mammals, the suprachiasmatic nucleus (SCN) acts as a circadian pacemaker (CPM)
which collects light signals from the retina, and directly influences pineal melatonin biosynthesis
as an output.[40] The rhythmic pattern of activity of the melatonin pathway (i.e., higher
concentration at night and a low level during the day) is conserved among vertebrates, congruent
with this hormone’s role as the time-keeper molecule.

1.3 Insect-type AANAT and Associated Biogenic Amines
AANATs perform diverse roles in physiological and behavioral regulation in insects and
arthropods. Insect AANAT (iAANAT) is involved in the suppression of black pigmentation
(known as melanism), as well as sclerotization of the cuticle by N-acetylating amines to provide
reactive quinones for linking chitin and arthropodins.[41-43] iAANAT also inactivates biogenic
amines such as dopamine, serotonin, octopamine, tryptamine, and norepinephrine by Nacetylation (arylalkylamine + acetyl-CoA → N-acetylarylalkylamine + CoA-SH). These
arylalkylamines have been suggested to act as potent neurotransmitters, neurohormones, and
neuromodulators through their binding to specific receptors.[44-46] This is in stark contrast to the
metabolic pathways of neurotransmitter monoamines in vertebrates, in which these compounds
are mainly metabolized by monoamine oxidases (MAO1 and 2). In arthropods, MAO activity is
limited or nonexistent, and the amines are catabolized primarily by NATs instead.[47] In
addition, iAANAT has been found to control developmental events and photoperiodism via
melatonin in certain species: orally-administered melatonin synchronizes circadian locomotor
rhythms of the house cricket, Acheta domesticus,[48] and stimulates the release of a
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prothoracicotropic hormone (PTTH) in the brain of cockroach Periplaneta americana, which
influences eclosion, molting, and diapause. [49-50]
AANAT-produced melatonin serves many roles in vivo, including anatomical and
behavioral functions, as well as antioxidant protection.[51-56] Melatonin is a potent scavenger of
free radicals, and is more affective at reducing oxidative damage than the classic antioxidants
glutathione, vitamin C, and vitamin E.[55] Animal AANAT is localized in the mitochondria,
while the serotonin N-acetyltransferase (SNAT) homologs found in higher plants and
cyanobacteria are found in both the mitochondria and chloroplasts. These organelles are the sites
of metabolic respiration and photosynthesis, and thus constitute the main source of free radicals
generated in the cell. Having acquired the ability to synthesize melatonin, these organelles can
better reduce oxidative damage from reactive oxygen species (ROS). It is theorized that
chloroplasts and mitochondria were originally transferred from a bacterial species through
endosymbiosis with their eukaryotic host cells, and the highly-conserved functions for melatonin
synthesis were retained over the course of evolution.[28]
As previously mentioned, N-acetyltransferase was first studied in conjunction with
sclerotization of the insect cuticle.[57] NATs are responsible for producing N-acetylated biogenic
amines (such as N-acetyldopamine) which are precursors used to couple chitin and arthopodin
via monoamine quinones. Other substrates for this sclerotization pathway include
catecholamines and phenolamines such as octopamine, tyramine, tryptamine, and
norepinephrine. In vertebrates, these amines are metabolized by MOAs, but this pathway is
absent from insects, where the monoamines are in high concentration during molting cycles.[58]
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1.4 The Discovery and Characterization of iAANAT
The pioneering identification and isolation of AANAT in vertebrates proved exceedingly
difficult: this enzyme is highly light-sensitive, and detection required Bolton-Hunter labeling
with a yield too small for sequence determination.[59] In fact, differential cloning successfully
identified AANAT before purification efforts were completed.[60-61] However, iAANAT was
much more photorefractory, and was successfully purified via HPLC. The protein sequence was
determined from cleavage products from cDNA cloned from the male gonad of P. americana.[62]
Chromatographic isolation and characterization revealed at least two types of NATs occurred in
different fractions, defined by pH optima and substrate specificity. These two variants were
designated NATa and NATb, with pH optima at acidic and basic ranges, respectively. Different
insect organs (CNS, midgut, and reproductive glands of both sexes) accommodate different
ratios of the protein forms, while the two types exhibit varying affinities to serotonin, tryptamine,
and octopamine.[63] This was the first evidence that suggested AANAT activities consist of a
family of enzymes.
iAANAT activity in Drosophila melanogaster was first discovered in 1972,[58] followed
soon after by its initial characterization in 1977.[64] In 1995, the Hintermann group successfully
purified the D. melanogaster AANAT,[45] which they later identified two biologically relevant
isoforms, variant A (AANATA) and variant B (AANATB).[65] The enzymes differ by a 35
amino acid leader peptide on the N-terminus of variant B, however our group showed no
enzymatic differences in binding or catalytic efficiency between the two forms.[17] AANATA
and AANATB are expressed in different tissues and at varying life stages, with AANATA
located in the brain, midgut, and ventral nerve cord during late-stage embryogenesis and in adult
flies. AANATB is less abundant, and is only evident in the brain in late-stage pupae and adults.
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Our group built upon this work and identified eight putative AANAT-like enzymes in D.
melanogaster which are proposed to play vital roles in the biosynthesis of fatty acid amides, one
of which catalyzes the formation of long-chain N-acylserotonins.[16, 18]
Since there is little similarity in the amino acid sequence homology of AANATs, the
ordinary PCR approach was unsuccessful in producing AANAT from the domesticated
silkworm, Bombyx mori. However, by recognizing conserved functional domains, Tsugehara, et
al, successfully amplified cDNA from the B. mori brain-subesophageal ganglion (SOG).[44] The
cDNA encodes a 261 amino acid protein with a wide range of substrate affinities, including
serotonin, dopamine, tryptamine, norepinephrine, and octopamine. The transcript was found in a
multitude of different tissues (head, ovary, testes, and flight muscles) over several developmental
stages: eggs, larvae, and adults. Recent work by the Zhu group identified a second novel B. mori
AANAT (which they termed Bm-iAANAT2) that when knocked down, lead to a change in
dopamine levels which can affect melanism.[66] Our group has discovered a third, previously
uncharacterized B. mori AANAT (Bm-iAANAT3), which will be the focus of the work in
Chapter 2.

1.5 The Role of iAANAT in Insect Circadian Rhythms and Photoperiodism
Amherd and Hintermann demonstrated that melatonin rhythms had bimodal peaks in D.
melanogaster; however, both AANAT enzymes failed to display circadian fluctuations in
transcript concentrations.[45, 65, 67] Interestingly enough, the opposite was true for Antheraea
pernyi (Chinese oak moth), B. mori, and P. americana: AANAT showed a circadian rhythm in
activity and in transcription.[41, 50, 63, 68] It was concluded that the circadian system controls both
AANAT transcription and expression; this in turn results in circadian fluctuations between
12

serotonin and melatonin, both daily and seasonally. An expressed serotonin receptor in the
PTTH neuron then blocks the release of prothoracicotropic hormone, and induces and maintains
diapause.[28] Seasonal changes in day-length affect AANAT activity: it is up –regulated by long
day conditions and down-regulated on shorter days. Therefore, iaanat acts as a clock-controlled
gene (CCG), where photoperiodism depends on a dual-control mechanism of diapause induction
and maintenance versus diapause termination.[68]
This was a striking discovery because iAANAT does not display timezyme functions,
despite the findings that it is the critical point between the circadian system and photoperiodism
in A. pernyi.[68] iAANAT shares several similarities to vtAANAT in the endocrine switch, as
supported by the following evidence. (1) iaanat is highly controlled by a negative feedback loop
via several E-box elements: four canonical E-boxes (CANNTG) and two perfect E-boxes
(CACGTG), all found in the iaanat promoter region.[28] As mentioned previously, qRT-PCR
exhibited rhythmical expression of iaanat in the light-dark cycle. RNAi knockdown of per (a
putative negative regulator of E-box) resulted in an up-regulation of aanat transcription. In
contradiction, RNAi used against Clk and cyc, positive regulators of E-box, suppressed the
expression levels of aanat. These results are similar to findings in chickens, where the
abundance of vtAANAT mRNA exhibits circadian rhythms in the pineal gland, which is
controlled by BMAL1/MOP4 and BMAL1/CLOCK heterodimers via E-box regulation.[26, 69] (2)
iAANAT contributes to insect photoperiodism. When pupae were injected with dsRNAiAANAT,
they failed to emerge, even under long day conditions. Pupae injected with dsRNAper showed a
higher proportion of emergence, including under short day settings. In mammals, nocturnallysecreted melatonin provides an endocrine signal of photoperiod to the pars tuberalis (the anterior
lobe of the pituitary gland); this, in turn, regulates a thyroid-stimulating hormone which
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modulates seasonal reproduction.[70] (3) Melatonin concentration is regulated by the expression
level of iaanat. Melatonin levels were significantly higher than control subjects after the
knockdown of per after 24 hours, however the injection of dsRNAiAANAT into pupae induced a
large decline of melatonin over 48 hours. In vertebrates, pineal melatonin concentration is
influenced by the changes in activity and expression levels of vtAANAT, which increases 10- to
100-fold at night.[39] Finally, (4) iAANAT is located within unique neuroendocrine cells which
control photoperiodism. iAANAT-like immunoreactivity was observed in a pair of co-localized
putative “clock neurons,” which is reflective of vtAANAT expression in the pineal gland,
proximal to the pars tuberalis.[70]
As previously noted, AANAT activity exhibits a nocturnal increase which produces
dramatically more melatonin during night hours. An elegant study conducted in 1972 by
Deguchi and Axelrod first measured the activity of AANAT via a radioenzymatic assay utilizing
[14C]-acetyl CoA. This highly sensitive analysis detected a 50-fold increase of AANAT activity
in the rat pineal gland at night.[71] Another study performed by Korf in 1994 discovered that
AANAT activity (and the consequent melatonin secretions) is abolished by light signals received
in photoreceptors dictated by peripheral oscillators.[72] In mammals, photoreception occurs first
in the retina, which induces endogenous oscillation in the SCN, and then finally produces
melatonin secretions in the pineal gland. However, the action of phototransduction for AANAT
regulation in invertebrates remains unclear. Recent findings regarding spectral responses have
illustrated that visual pigments may mediate light-induced suppression of AANAT activity in
these organisms, analogous to melanopsin in vertebrates.[73] In C. elegans and the band-legged
cricket D. nigrofasciatus, blue light is the most effective in suppressing AANAT activity (at
wavelengths of 500 nm and 450 nm, respectively), [74-75] while the mite T. urticae exhibits two
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wavelengths of enzyme activity suppression (UV-A at 350 nm and blue light at 450 nm). These
spectral characteristics imply that certain short-wave photopigments may serve as the input
system for phototransduction in regards to AANAT regulation in invertebrates.[28]

1.6 Outline of the Research and Experimentation Detailed in this Dissertation
The following chapters of this dissertation will pertain to the work conducted on a set of
several enzymes produced and studied in the Merkler lab, three of which are completely novel.
Chapter 2 expounds on our work with iAANAT from B. mori, where we demonstrate that BmiAANAT is capable of catalyzing the condensation of long-chain acyl-CoA substrates with
various biogenic amines. We also delineate the full catalytic mechanism of Bm-iAANAT-3, a
previously unstudied enzyme from this model organism. This data, as well as ongoing efforts to
acquire crystal structures of these AANAT enzymes, segues into our expertise in synthesizing
activity-based protein profiling (ABPP) probes for the selective enrichment of enzymes from
various organs, tissues, and/or entire cell lysates. In Chapter 3, we detail the development and
utilization of a probe used to enrich proteins that bind adenine and adenosine nucleotides,
collectively known as AdoRs. This research has far-reaching implications in cancer-based
proteomics, and we hope further studies will eventually help to elucidate novel NAT enzymes
from mammals using similarly devised probes. Finally, Chapter 4 presents our work on DXS,
the first and rate-limiting enzyme of isoprenoid biosynthesis in the malaria-causing protists
Plasmodium falciparum and Plasmodium vivax. By studying the mechanism of binding for these
enzymes, we hope to contribute to ongoing efforts to develop novel antimalarial compounds.
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CHAPTER TWO:
A PAIR OF ARYLALKYLAMINE N-ACYLTRANSFERASES FROM BOMBYX MORI:
PREVIOUSLY UNIDENTIFIED LONG-CHAIN N-ACYLARYLALKYLAMINE
BIOSYNTHESIS & THE FULL MECHANISTIC ANALYSIS OF A NOVEL INSECT
AANAT ENZYME

2.1 An Introduction to Bombyx mori iAANAT
Arylalkylamine N-acyltransferase (AANAT) catalyzes the N-acylation of arylalkylamines
with acyl-CoA substrates, and has been intensely studied in mammals where it has earned the
moniker “timezyme” due to its role in diurnal melatonin production.[1-6] In this pathway,
AANAT serves as the penultimate and rate-limiting enzyme responsible for acetylating serotonin
to form N-acetylserotonin (NAS). NAS is then methylated by hydroxyindole-Omethyltransferase (HIOMT) to melatonin. However, for all we know about the role of this
enzyme in vertebrates, much less is known about AANAT in insects (iAANAT), where it has
been implicated in a wide variety of biophysical functions. iAANAT performs vital reactions in
the inactivation of monoamine neurotransmitters, sclerotization of the insect cuticle, suppression
of melanism, production of melatonin, and is involved in seasonal photoperiodism and
developmental events such as eclosion, molting, spinning activity, and diapause.[7-11]
To date, a pair of recombinant AANAT enzymes have been cloned and characterized
from the domesticated silkworm, Bombyx mori, an important economic insect and molecular
model. Tsugehara, et al. first studied Bm-iAANAT in 2007, where its mRNA expression was
found in eggs, larvae, adult flies and various tissues.[12] This result hinted that Bm-iAANAT may
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be involved in the general metabolism of monoamines in various tissues, in contrast to
vertebrates where AANATs are found primarily in the pineal gland and retina. The identity and
similarity between the deduced amino acid sequences of DmA-iAANAT1 (from D.
melanogaster) and Bm-iAANAT were 27.8% and 49.8%, respectively, while the identity and
similarity of Bm-iAANAT with sheep AANAT were lower at 20.9% and 32.6%, respectively.
Analysis with the Pfam database confirmed that Bm-iAANAT contained an acetyltransferase
domain of the GCN5-related N-acetyltransferase (GNAT) superfamily, consistent with studies
pertaining to other N-acyltransferase enzymes.[13] They also conducted various kinetic analyses,
and detected AANAT activity when serotonin, octopamine, dopamine, norepinephrine,
tryptamine, or tyramine was used as a substrate with acetyl-CoA. Since AANAT activity and
melatonin are both detected in the silkworm head,[7] and Bm-iAANAT acetylated serotonin and
the mRNA transcript was also expressed in this region, the group reasoned this enzyme may be
related to melatonin production in the head of B. mori.
Diverse substrate specificity, in addition to broad tissue distribution, suggests that BmiAANAT may be implicated in sclerotization of the insect cuticle (N-acetyldopamine and Nacetylnorepinephrine are precursors used to couple chitin and arthopodin via monoamine
quinines) and could be a major enzyme in the catabolism of monoamines. The biosynthesis and
degradation of these important neurotransmitters must be maintained at appropriate cellular
levels, and dysfunction in either of these opposing pathways would lead to errors in the processes
regulated by them.[14] Dai et al. also studied Bm-iAANAT and its role in melanism.[9] In
Bombyx mori, roughly 100 gene mutation systems are associated with aberrant color patterns.
One such mutation is the melanism (mln) mutant, a rare body coloration abnormality that leads to
darker pigmentation. A family of AANAT enzymes converts dopamine to N-acetyldopamine, a
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precursor to the colorless N-acetyldopamine sclerotin; however, the dysfunction of AANAT
expression may be related to melanism in insects. The group concluded that the candidate gene
of the mln locus was bm-iaanat, and found that dopamine content was twice as high in sclerified
tissues compared to wild type. They proposed that the higher concentration of dopamine was a
direct result of the functional deficiency of bm-iaanat in the mutant, causing darker coloration in
sclerified regions.[9]
Long et al. have recently discovered and characterized a second AANAT enzyme from B.
mori, Bm-iAANAT2. [15] This protein shares 57% amino acid identity with Bm-iAANAT and
was strongly expressed in the head, midgut, fat body, integument tubules, sex organs, and
hemocyte. The group constructed transgenic flies where Bm-iAANAT2 expression was
suppressed, and subsequently identified increased melanin deposition in the head and
integument. Dopamine levels were elevated in the head, thus confirming a reduction in AANAT
activity lead to changes in melanism patterns. They also cloned and expressed recombinant BmiAANAT2, and found it acetylated tryptamine to form N-acetyltryptamine, displaying weak in
vivo activity.
In addition to its role in the inactivation of primary amines through N-acetylation, it was
postulated that AANATs may exist that catalyze the direct conjugation of long-chain acyl-CoAs
to various biogenic amines to form the N-acylarylalkylamides. This class of fatty acid amide is
an emerging class of cell signaling lipids, and their biosynthetic routes in vivo are largely
unidentified (with the exception of N-arachidonoylethanolamine, or anandamide, which has been
extensively studied). Recent work by Dempsey et al. elucidated the first AANAT that catalyzed
the formation of long-chain N-acylserotonins and N-acyldopamines in D. melanogaster,
compounds suggested to act as potent neurotransmitters.[16] This enzyme, termed Dm29

AANATL2, displayed chemistry consistent with reactions catalyzed by similar arylalkylamine
N-acetyltransferases and other proteins of the GCN5-related N-acetyltransferase (GNAT) family
of enzymes.
In this chapter, we outline our work with Bm-iAANAT, as well as a novel AANAT from
Bombyx mori. We reasoned that previous kinetic analyses of Bm-iAANAT were limited in their
extent of substrate screening; therefore, this formerly characterized enzyme was extensively
assayed with assorted long-chain acyl-CoA substrates. We found that this enzyme does indeed
catalyze the conjugation reaction of several amines with various long-chain CoAs of different
lengths, a previously overlooked aspect of Bm-iAANAT catalysis.
Furthermore, we cloned and characterized a novel AANAT enzyme from B. mori, which
we have designated Bm-iAANAT3. This enzyme displays broad specificity with short-chain
acyl-CoAs exclusively, with catalytic rates roughly 600x greater than Bm-iAANAT (when
catalyzing the N-acetylation of tryptamine with acetyl-CoA). We conducted several analyses to
solve the kinetic mechanism, including double-reciprocal analysis, dead-end inhibition, pHactivity profiling, and site-directed mutagenesis experiments to elucidate the first proposed
chemical mechanism of an AANAT from Bombyx mori.

2.2 Experimental Procedures
2.2.1 Materials and General Methods
Unless otherwise noted, all reagents were obtained from commercial sources. Codonoptimized Bm-iAANAT and Bm-iAANAT3 were purchased from Genscript. Oligonucleotides
were purchased from Eurofins MWG Operon. BL21 (DE3) E. coli cells, XL-10 competent cells,
and the pET-28a(+) vector were purchased from Novagen.
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PfuUltra High-Fidelity DNA

polymerase was purchased from Agilent. XhoI, NdeI, Antarctic Phosphatase, and T4 DNA
ligase were purchased from New England Biolabs. Kanamycin monosulfate and IPTG were
purchased from Gold Biotechnology.

ProBond nickel-chelating resin was purchased from

Invitrogen. Long and short-chain acyl-CoAs and amine substrates were purchased from SigmaAldrich. All other supplies and materials were of the highest quality available from either Sigma
or Fisher Scientific. Spectrophotometric analyses were performed on a Cary 300 Bio UV-Visible
spectrophotometer.
2.2.2 Molecular Cloning of Bm-iAANAT and Bm-iAANAT3
Bm-iAANAT (Accession No. NM_001079654.2) and Bm-iAANAT3 (Accession No.
NM_001190842.1) were codon optimized for expression in E. coli, with 5’-NdeI and 3’-XhoI
restriction sites, and synthesized into a pUC57 vector. The full-length gene was excised from the
pUC57 vector and cloned into the NdeI and XhoI restriction sites of the pET-28a vector. The
Bm-iAANAT-pET28a and Bm-iAANAT3-pET28a vectors were then transformed into E. coli XL10 competent cells, plated on a Luria Broth (LB) agar plate supplemented with 50 μg/mL
kanamycin, and grown overnight at 37°C. A single colony from each vector transformation was
cultured overnight in LB media supplemented with 50 μg/mL kanamycin overnight at 37°C. The
Bm-iAANAT-pET28a and Bm-iAANAT3-pET28a plasmids were purified from the overnight
cultures using the Promega Wizard Plus SV Minipreps DNA purification kit, sequenced by
Eurofins MWG Operon to confirm correct gene insertion, and finally transformed into E. coli
BL-21 (DE3) cells for the expression of either Bm-iAANAT or Bm-iAANAT3.
2.2.3 Protein Expression and Purification
The E. coli BL-21 (DE3) competent cells containing either the Bm-iAANAT-pET28a or
Bm-iAANAT3-pET28a vector were cultured in LB media supplemented with 50 μg/mL
31

kanamycin at 37°C. Once the cultures reached an OD600 of 0.6, cells were induced with the
addition of 1.0 mM isopropyl β-D-thiogalactopyranoside (IPTG) for 4 hours at 37°C. The final
cultures were harvested by centrifugation at 6,000g for 10 minutes at 4°C, and pellets were
frozen at -80°C for later analysis.
Cell pellets were thawed and resuspended in Binding buffer: 20 mM Tris pH 7.9, 500
mM NaCl, and 5 mM imidazole. Cells were lysed by sonication and the cellular debris was
pelleted by centrifugation at 16,000g for 20 minutes at 4°C. The supernatant was retained and
loaded onto a 5 mL of ProBond nickel-chelating resin. The column was washed with 5 column
volumes (CVs) of Binding buffer, followed by 10 CVs of Wash buffer: 20 mM Tris pH 7.9, 500
mM NaCl, and 60 mM imidazole. Finally, purified enzyme was eluted from the column in 1 mL
fractions with 2-3 CVs of Elution buffer: 20 mM Tris pH 7.9, 500 mM NaCl, and 500 mM
imidazole. Fractions were evaluated for purity and protein concentration using 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gels and Bradford binding
assay, respectively. Fractions containing purified AANAT enzyme were pooled, dialyzed
overnight in 20 mM Tris pH 7.4, 200 mM NaCl, and stored at -80°C.
2.2.4 Enzyme Screening Assay
Each Bombyx mori AANAT was subjected to an activity-based screening to elucidate
relevant substrates. First, each enzyme was evaluated using acetyl-CoA (representative of shortchain CoAs) or oleoyl-CoA (exemplary of long-chain CoA catalysis) separately, with different
groups of pooled amines. The groups of amines are listed in Table 2.1. The assay conditions
consisted of 300 mM Tris pH 8.0, 150 μM DTNB (5,5’-dithiobis(2-nitro-benzoic acid) or
Ellman’s reagent), 500 μM of either coenzyme A substrate, and 60 mM of each of the amine
pools at 22°C. Initial velocities were determined by measuring the release of CoA at 412 nm
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(molar extinction of Ellman’s reagent = 13,600 M-1 cm-1), with the reported velocities calculated
as the background hydrolysis rate subtracted from the observed velocity.
Table 2.1 Pooled amine substrates for the initial screening assay
Group
1
2
3
4
5
6
7
8

Amino Donors
Lysine, Threonine, Glycine, Histamine, Dopamine
Alanine, Arginine, Histidine, Tyramine, Norepinephrine
Serine, Proline, Methionine, Serotonin, Tryptamine
Glutamate, Asparagine, Valine, Ethanolamine, Octopamine
Aspartate, Isoleucine, Tryptophan, Glutamine
Leucine, Phenylalanine, γ-Aminobutyric acid, Taurine
Spermidine, Agmatine, Cadaverine, Putrescine, B-Alanine
Kanamycin, Neomycin A, Tobraymcin

Any CoA and amine group combination that displayed a background-corrected rate ≥ 0.1
μmoles/min/mg was considered a “significant velocity.” The corresponding amines were then
individually interrogated further at saturating conditions with the respective CoA to deduce
which were true substrates for AANAT. The assay conditions were identical as the pooled
screening step, and individual amines that displayed a rate of ≥ 0.1 μmoles/min/mg above
background were then assayed to determine steady-state kinetic constants (see section 2.2.5).
2.2.5 Activity Assay for Determining Steady-State Kinetic Constants
Steady-state kinetic characterization for both Bm-iAANAT and Bm-iAANAT3 were
assayed using Ellman’s reagent by measuring the release of coenzyme A at 412 nm under the
following conditions: 300 mM Tris pH 8.0, 150 μM DTNB, and varying concentrations of
substrates at 22°C. To test kinetic constants for Bm-iAANAT, the initial tryptamine
concentration was held at 60 mM while the long-chain acyl-CoA substrates were varied. To
assay the kinetic constants for the amines, tryptamine, tyramine, octopamine, and serotonin were
varied while oleoyl-CoA was held at 100 μM. For assaying the kinetic constants of Bm33

iAANAT3, tryptamine was held constant at 8 mM while the short-chain acyl-CoA substrates
were varied. Alternatively, the significant amino donors were assayed while acetyl-CoA was
held at 500 μM. The apparent kinetic constants were determined by fitting the resulting data to
Equation 2.1 using SigmaPlot 12.0: vo represents initial velocity, Vmax,app is the apparent maximal
velocity, Km,app is the apparent Michaelis constant, and [S] is the substrate concentration. Assays
were performed in triplicate and the uncertainty for the kcat,app and (kcat/Km)app values were
calculated using Equation 2.2, where σ is the standard error.[17]

Equation 2.1

vo =

Vmax,app [S]
K m,app + [S]

Equation 2.2

σy 2
x
x σx 2
√
σ( ) =
( ) +( )
y
y
x
y

2.2.6 Bm-iAANAT Product Characterization
To confirm the product formation of Bm-iAANAT, 1 mM tryptamine and 500 μM of
oleoyl-CoA were incubated with 100 μg of the enzyme for 1 hour in 300 mM Tris pH 8.0 (this
ratio of substrates was deemed ideal after several optimization studies, since Bm-iAANAT is
easily inhibited by an excess of amine donor).[12] The reaction mixture was then passed through
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a 10 kDa ultrafilter (Millipore) to remove the enzyme. No enzyme blanks were also prepared. 20
μL of the resulting flow-through solution containing the oleoyl-tryptamine conjugation product
was injected on an Agilent 6540 liquid chromatography/quadrupole time-of-flight mass
spectrometer (LC/QTOF-MS) in positive ion mode. Product separation was completed on a
Kinetex 2.6 μm C18 100 Å (50 x 2.1 mm) reverse phase column with the following mobile phase
gradient: mobile phase A consisted of water with 0.1% formic acid, while mobile phase B was
comprised of acetonitrile with 0.1% formic acid. A linear gradient of 10% mobile phase B
increased to 100% B over 5 minutes, followed by a hold-up of 3 minutes at 100% B for the
liquid chromatography analysis of the product. The column was then equilibrated with 10%
mobile phase B for 10 minutes before subsequent injections.
2.2.7 Kinetic Mechanism Elucidation of Bm-iAANAT3
2.2.7.1 Double Reciprocal Analysis
To delineate between a sequential and classic ping-pong mechanism, double-reciprocal
plots of the initial velocity data were generated for acetyl-CoA and tryptamine in SigmaPlot
12.0. Non-linear regression analysis of initial rates and model discrimination analyses were
performed in WaveMetrics IGOR Pro 6.34A. Initial velocities were determined by varying the
concentration of one substrate, while holding the other substrate at a fixed concentration. The
two plots were generated by holding the tryptamine concentration constant (50 μM, 100 μM, 250
μM, and 500 μM) and varying the concentration of acetyl-CoA. Accordingly, the second plot
held the concentration of acetyl-CoA constant (45 μM, 90 μM, 225 μM and 450 μM) and varied
the tryptamine concentration. The resulting initial velocity data was fit to Equation 2.3 for an
ordered Bi-Bi mechanism, where vo is the initial velocity, Vmax is the maximal velocity, [A] is
35

the concentration of substrate A, [B] is the concentration of substrate B, Kia is the dissociation
constant for substrate A, Kb is the Michaelis constant for substrate B, and Ka is the Michaelis
constant for substrate A.

Equation 2.3
vo =

Vmax [A][B]
K ia K b + K a [B] + K b [A] + [A][B]

2.2.7.2 Dead-end Inhibition with Oleoyl-CoA and Tyrosol
To further explicate the kinetic mechanism of Bm-iAANAT3, we used dead-end
inhibition analysis using oleoyl-CoA and tyrosol. The initial velocities were generated by
holding one substrate (either acetyl-CoA or tryptamine) at a fixed concentration, varying the
concentration of the other substrate, at different fixed concentrations of each inhibitor. All
assays were performed in triplicate, and the resulting data was fit to Equations 2.4 – 2.6 in
SigmaPlot 12.0 for competitive, noncompetitive, and uncompetitive inhibition, respectively. For
Equations 2.4 – 2.6, vo is the initial velocity, Vmax,app is the apparent maximal velocity, Km,app is
the apparent Michaelis constant, [S] is the substrate concentration, [I] is the inhibitor
concentration, and Ki is the inhibition constant.
Equation 2.4

vo =

Vmax,app [S]
[I]
K m,app (1 + K ) + [S]
i
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Equation 2.5

vo =

Vmax,app [S]
[I]
[I]
K m,app (1 + K ) + [S] (1 + K )
i
i

Equation 2.6

vo =

Vmax,app [S]
[I]
K m,app + [S] (1 + K )
i

2.2.7.3 Bm-iAANAT3 Rate versus pH Dependence
The pH dependence on the apparent kinetic constants was determined for both tryptamine
and acetyl-CoA, at intervals of 0.5 pH units ranging from pH 6.5 to 9.5. The buffers used
consisted of the following: MES (pH 6.5), Tris (pH 7.0 – 9.0) and AmeP (pH 9.0 – 9.5). The
resulting kinetic data were fit to Equations 2.7 and 2.8 in WaveMetrics IGOR Pro 6.34A to
delineate the apparent pKa values of measured ionizable groups. In both equations, c is the pHindependent plateau.

Equation 2.7

log(k cat /K m )app = log[c/(1 + 10pKa −pH )]
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Equation 2.8

log k cat,app = log[c/(1 + 10pKa −pH )]

2.2.7.4 Generation of Site-directed Mutants
To further investigate the role of amino acid residues possibly implicated in binding and
catalysis, a pair of Bm-iAANAT3 mutants was produced: E27A and S167A. The generation of
both mutants was facilitated through the overlap extension method.[18] Mutants were amplified
with the PfuUltra High-Fidelity DNA polymerase with the following PCR conditions: an initial
denaturation step of 95°C for 2 minutes, followed by 30 cycles of PCR amplification (95°C for
30 s, 58°C for 30 s, 72°C for 1 min), and a final extension step of 72°C for 10 minutes. Primers
were designed on the Agilent QuickChange Primer Design tool (Table 2.2) and purchased from
Eurofins MWG Operon. PCR products were digested with NdeI and XhoI restriction enzymes
and ligated into the pET28a vector with DNA ligase acquired from New England Biolabs.
Mutant enzymes were expressed and purified in the same manner as the wild type Bm-iAANAT3
(see section 2.2.3).
Table 2.2 Bm-iAANAT3 site-directed mutagenesis primers
Clone
Full Gene
E27A
S167A

Primer
Forward
Reverse
Antisense
Sense
Antisense
Sense

Sequence
GTAGCATATGGCTGATTTTGTTGTTGT
GTAGCTCGAGTTACGGCAGTTTCAG
TCCTTCTTTGCCGATGCACCGCTGAACAAAGCC
GGCTTTGTTCAGCGGTGCATCGGCAAAGAAGGA
GGCAGATACGTTGAGCAAAGGCGCCGGTC
ACCGGCGCCTTTGCTCAACGTATCTGCC
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2.3 Experimental Results
2.3.1 Cloning, Expression, and Purification of Bm-iAANAT Enzymes
Both Bm-iAANAT and Bm-iAANAT3 from Bombyx mori were successfully cloned,
expressed, and purified from codon-optimized genes to yield 17.4 mg and 10.9 mg of purified
protein per liter of culture, respectively. Purity was assessed to be ≥95% by a 10% SDS-PAGE
gel (see Figure 2.1) and both protein bands are in good agreement with their predicted masses
(29.6 kDa for Bm-iAANAT and 23.9 kDa for Bm-iAANAT3).

Figure 2.1 SDS-PAGE analysis. (A) Bm-iAANAT and (B) Bm-iAANAT3.
Bm-iAANAT3 is a previously uncharacterized enzyme, and shares 25.3%, 23.4%, and
26.5% sequence identity with Bm-iAANAT, Bm-iAANAT2, and Dm-AANATA, respectively
(Figure 2.2). It shares slightly less identity with the mammalian AANATs from human and
sheep, at 20.8% and 16.8% identity, respectively. This analysis further confirms that these and
other AANATs share poor homology, even from organisms of the same phylum and class.
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Figure 2.2 Homology overlays of several AANAT enzymes from B. mori and D. melanogaster.

2.3.2 Pooled Screening for the Elucidation of Bombyx mori AANAT Substrates
2.3.2.1 Bm-iAANAT Screening with Long-Chain Acyl-CoA Substrates
Our lab has developed a screening method comprised of eight groups of various amine
substrates (arylalkylamines, polyamines, aminoglycosides, ethanolamine, histamine, and the
cognate amino acids) that can be tested with both short and long-chain acyl-CoA substrates. The
concentration of the amines in the screening assay were held at high concentrations since some
GNAT enzymes have been reported with high Km,app values: mouse GLYAT has a Km,app of 6
mM for glycine.[19] Pools of acyl-CoA substrates were not constructed because of numerous
accounts of long-chain acyl-CoAs acting as inhibitors;[20] therefore, we individually screened
archetypal short and long-chain thioesters in the form of acetyl-CoA and oleoyl-CoA (which has
been reported previously as a substrate for several GNAT enzymes).[21] The benefits of this
technique are clear: any pool that shows no catalytic activity can be entirely disregarded for
individual kinetic assessment. When this strategy was applied to Bm-iAANAT with acetyl-CoA,
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significant velocities (a background-corrected rate ≥ 0.1 μmoles/min/mg) were achieved with
five of the eight amine substrate groups, confirming the promiscuous nature of this enzyme (see
Table 2.3). In addition to the amino donors already identified by Tsugehara et al. (tryptamine,
serotonin, octopamine, dopamine, norepinephrine, etc.), we ascertained several previously
unknown Bm-iAANAT substrates: lysine, histamine, alanine, tyramine, ethanolamine, as well as
several polyamines including spermidine, agmatine, cadaverine, and putrescine. However,
because of limitations of using Ellman’s reagent at low substrate concentrations (below ~1 μM),
our spectrophotometric assay was not sensitive enough to calculate kinetic constants for many of
the amines. Several of the potential substrates that were hits from our screening method
(tryptamine, dopamine, serotonin, tyramine, etc) had (Km, acetyl-CoA)app values of approximately 1
μM or lower; Tsugehara et al. used a more sensitive [14C] acetyl-CoA radiocarbon assay and
derived Km,app values of 0.31 μM and 1.7 μM for acetyl-CoA and tryptamine, respectively.[12]

Table 2.3 Pooled screening results for Bm-iAANAT and Bm-iAANAT3.
AcylCoA

1

2

Acetyl
Oleoyl

1.18a
0.02

1.32a
0.88a

Acetyl
Oleoyl

47.5a
0.01

48.1a
0.02

Velocity (μmoles/min/mg)
Group
3
4
5
Bm-iAANAT
1.03a
1.22a
0.01
a
0.91
0.59a
0.02
Bm-iAANAT3
a
51.2
12.4a
0.04
0.01
0.03
0.02

6

7

8

0.04
0.02

1.96a
0.01

0.01
0.00

0.07
0.01

0.09
0.04

0.04
0.01

Constitutes a “significant velocity” (a background-corrected rate ≥ 0.1 μmoles/min/mg). The
assay conditions consisted of 300 mM Tris pH 8.0, 150 μM (DTNB), 500 μM of either
coenzyme A substrate, and 60 mM of each of the amine pools at 22°C.
a
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Nevertheless, the diverse set of amine donors that acted as substrates and the
promiscuous nature of Bm-iAANAT was encouraging, for we hypothesized this enzyme may be
capable of catalyzing the formation of the long-chain N-acylarylalkylamides. When the pooling
strategy was repeated with oleoyl-CoA, three of the eight groups yielded significant velocities.
Individual interrogation of these groups provided four positive results with a long-chain acylCoA thioester: tryptamine, tyramine, serotonin, and octopamine (see Table 2.4)
Table 2.4 Individual amine substrate specificity for Bm-iAANAT with oleoyl-CoA.
CoA
(100 μM)
OleoylCoA

Varied
Amine
Tryptamine
Tyramine
Octopamine
Serotonin

Km, app
(mM)
7.0 ± 0.5
84 ± 12
65 ± 16

kcat, app
(kcat/Km)app
Relative
(s-1)
(M-1 s-1)
(kcat/Km)app
0.72 ± 0.01 (1.0 ± 0.07) x 102
22
2.7 ± 0.19
32 ± 5.3
6.8
0.31 ± 0.04
4.7 ± 1.2
1.0
Precipitation at High Concentration

The four arylalkylamines that had “significant velocities” (background-corrected rates ≥ 0.1
μmoles/min/mg) in the individual pooling assay when reacted with oleoyl-CoA.

Tryptamine was the “best” substrate for conjugation with oleoyl-CoA, with a Km,app of
7.0 ± 0.5 mM and a (kcat/Km)app of (1.0 ± 0.07) x 102 M-1s-1. Tyramine and octopamine displayed
significantly higher Km,app values of 84 ± 12 and 65 ± 16 mM, respectively. Unfortunately, at
high concentrations, the formation of oleoyl-serotonin produced a precipitate that made
spectrophotometric analysis impossible. Yet, qualitatively speaking, the release of CoA-SH was
clearly evident with the DTNB assay, due to its intense yellow color. More optimization is
required to define kinetic constants for this substrate.
To elucidate steady-state kinetic constants for Bm-iAANAT, we first varied tryptamine
concentration while holding the concentration of several acyl-CoAs constant at 100 μM (Table
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2.5). The (Km, tryptamine)app values are all comparable, ranging from 2.5 mM to 7.0 mM. There is
also an explicit trend in regards to the acyl-CoA chain length. The (kcat/Km)tryptamine,app was
highest when the thioester substrate was lauroryl-CoA ((3.1 ± 0.5) x 102 M-1s-1) and continued to
decline as the acyl chain length was increased. We then evaluated various acyl-CoA thioesters to
ascertain whether or not chain length affected catalysis (Table 2.6). When tryptamine was held
constant at saturating conditions and the concentration of the CoA substrate was varied, we again
observe the same pattern: higher (kcat/Km)acyl-CoA,app values with shorter acyl-chain lengths that
decreased as the alkyl moiety was extended. This suggests that the longer chain lengths of the
acyl-CoA substrates may disrupt binding of the amine substrate, hindering catalysis. Tsugehara
et al. assessed Bm-iAANAT under similar conditions, and calculated (Km,acetyl-CoA)app and
(kcat/Km)acetyl-CoA,app values of 0.31 μM and 3.8 x 105 M-1s-1, respectively.[12] These data suggest
that Bm-iAANAT is catalytically more efficient at using the longer chain acyl-CoA substrates
(up to palmitoyl-CoA) than acetyl-CoA when tryptamine is the corresponding amine in catalysis.
Table 2.5 Apparent steady-state kinetic constants of Bm-iAANAT when tryptamine was varied
and the acyl-CoA substrates were held constant.
Varied
Amine

CoA
(100 μM)a

Chain
Length

Km, app
(mM)

kcat, app
(s-1)

(kcat/Km)app
(M-1 s-1)

Relative
(kcat/Km)app

Lauroryl

12:0

5.9 ± 1.0

1.8 ± 0.07

(3.1 ± 0.5) x 102

3.1

Myristoyl

14:0

2.5 ± 0.2

0.66 ± 0.01

(2.7 ± 0.3) x 102

2.7

Palmitoyl

16:0

3.0 ± 0.4

0.51 ± 0.01

(1.7 ± 0.2) x 102

1.7

Oleoyl

18:1

7.0 ± 0.5

0.72 ± 0.01

(1.0 ± 0.07) x 102

1.0

Tryptamine

a

Background rates of acyl-CoA hydrolysis were obtained at saturating CoA concentrations in the
absence of tryptamine, and subtracted from the rates in the presence of tryptamine. Background
hydrolysis rates were ≤5% of the catalytic rates in the presence of tryptamine.
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Table 2.6 Apparent steady-state kinetic constants of Bm-iAANAT when tryptamine was at
saturating conditions and the acyl-CoA substrates were varied.
Amine
(60 mM)

Tryptamine

Varied
CoAa

Chain
Length

Km, app
(μM)

kcat, app
(s-1)

(kcat/Km)app
(M-1 s-1)

Relative
(kcat/Km)app

Lauroryl

12:0

0.97 ± 0.12

1.3 ± 0.01

(1.4 ± 0.2) x 106

6.2

Myristoyl

14:0

0.92 ± 0.20

0.66 ± 0.01

(7.2 ± 1.5) x 105

3.2

Palmitoyl

16:0

1.1 ± 0.30

0.51 ± 0.01

(4.9 ± 1.4) x 105

2.2

Oleoyl

18:1

1.7 ± 0.51

0.42 ± 0.02

(2.4 ± 0.7) x 105

1.1

Arachidoyl

20:4

1.2 ± 0.67

0.27 ± 0.02

(2.3 ± 1.3) x 105

1.0

a

Background rates of acyl-CoA hydrolysis were obtained at each CoA concentration in the
absence of tryptamine, and subtracted from the rates in the presence of tryptamine. Background
hydrolysis rates were ≤5% of the catalytic rates in the presence of tryptamine.

These data highlight the first AANAT identified in Bombyx mori that will catalyze the
formation of long-chain N-acylarylalkylamides. When we compare the steady-state kinetic
constants with those of Dm-AANATL2 from D. melanogaster (the first enzyme identified that
generates long-chain N-acylserotonins and N-acyldopamines), we observe nearly identical values
for (kcat/Km)oleoyl-CoA,app and (kcat/Km)amine,app (see tables 2.7 and 2.8 for comparisons of steadystate kinetic constants between these two enzymes). Dempsey et al. previously highlighted the
relatively low (kcat,amine)app and (kcat,acyl-CoA)app for Dm-AANATL2 which is also evident in BmiAANAT. Notwithstanding, these low values are unsurprising since it is postulated that the longchain N-acylarylalkylamides serve as potent cell signaling lipids, and the kcat,app values measured
are conceivably sufficient to supply cellular needs. It is possible that Bm-iAANAT is the enzyme
responsible for the generation of these long-chain N-acylarylalkylamides, while a more
catalytically potent Bombyx mori AANAT produces the short-chain compounds.
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Table 2.7 Comparisons of kinetic constants from Dm-AANATL2 versus Bm-iAANAT when the
amine substrate was saturating.
Enzyme
DmAANATL2

Varied CoA

Saturating
Amine

Km, app
(μM)

kcat, app
(s-1)

(kcat/Km)app
(M-1 s-1)

Acetyl-CoA1

Serotonin

6.1 ± 0.3

1.3 ± 0.012

(2.2 ± 0.02) x 105

Oleoyl-CoA1

Serotonin

3.6 ± 0.6

0.075 ± 0.003

(2.1 ± 0.09) x 104

Acetyl-CoA2

Tryptamine

0.31

0.11

3.8 x 105

Oleoyl-CoA

Tryptamine

1.7 ± 0.51

0.42 ± 0.02

(2.4 ± 0.7) x 105

Bm-iAANAT

1

Dempsey, et al., Identification of an AANAT from D. melanogaster... FEBS Lett. 2014, 588
(4), 594-599.
2
Tsugehara, T et al., Cloning and characterization of iAANAT from B. mori. Comp. Biochem.
Physiol. B-Biochem. Mol. Biol. 2007, 147 (3), 358-366.

Table 2.8 Comparisons of kinetic constants from Dm-AANATL2 versus Bm-iAANAT when
oleoyl-CoA was saturating.
Enzyme

Saturating
CoA

Varied
Substrate

Km, app
(mM)

kcat, app
(s-1)

(kcat/Km)app
(M-1 s-1)

Oleoyl-CoA1

Serotonin

0.5 ± 0.1

0.085 ± 0.006

(1.7 ± 0.12) x 102

Oleoyl-CoA1

Dopamine

1.2 ± 0.2

0.058 ± 0.003

(4.7 ± 2.7) x 102

Oleoyl-CoA

Tryptamine

7.0 ± 0.5

0.72 ± 0.01

(1.0 ± 0.07) x 102

Dm-AANATL2
Bm-iAANAT
1

Dempsey, et al., Identification of an AANAT from D. melanogaster... FEBS Lett. 2014, 588
(4), 594-599.

2.3.2.2 Bm-iAANAT3 Screening with Short-Chain Acyl-CoA Substrates
We again implemented our screening assay with the novel Bm-iAANAT3 enzyme,
however failed to achieve any significant velocities with oleoyl-CoA, suggesting this enzyme
does not catalyze the formation of long-chain N-acylamides. However, when the thioester
substrate was acetyl-CoA, we observed a broad range of specificity in regards to the amines, at
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rates nearly ~50x higher than that of Bm-iAANAT (see Table 2.3). When we further
investigated the individual amines from the four pools that were categorized as hits, we
elucidated six arylalkylamides and histamine that underwent catalysis. The order of substrates
ranked in decreasing rates of catalysis is as follows: tryptamine, tyramine, dopamine,
octopamine, serotonin, norepinephrine, and histamine (Table 2.9).

Table 2.9 Apparent steady-state kinetic constants of Bm-iAANAT3 when acetyl-CoA was held
constant at 500 µM and the amine substrate concentration was varied.
Amine

Km, app
(μM)

kcat, app
(s-1)

(kcat/Km)app
(M-1 s-1)

Relative (kcat/Km)app

Tryptamine

97 ± 8.8

60 ± 1.2

(6.2 ± 0.6) x 105

33

Tyramine

63 ± 6.7

27 ± 0.64

(4.3 ± 0.5) x 105

23

Dopamine

330 ± 23

55 ± 1.1

(1.6 ± 0.1) x 105

8.4

Octopamine

18 ± 0.77

2.2 ± 0.02

(1.2 ± 0.05) x 105

6.3

Serotonin

1100 ± 63

59 ± 1.0

(5.2 ± 0.3) x 104

2.7

Norepinephrine

140 ± 8.6

5.3 ± 0.07

(3.7 ± 0.2) x 104

1.9

Histamine

1700 ± 98

33 ± 0.68

(1.9 ± 0.1) x 104

1.0

Tryptamine catalysis was ~30x more potent than histamine, the least catalytic substrate.
Octopamine displayed the lowest Km,app value of 18 ± 0.77 µM, while histamine displayed the
highest Km,app of 1.7 ± 0.1 mM. One noticeable characteristic of all of these substrates is that
they each possess a two methylene spacer between the amino group and the aromatic moiety.
None of the polyamines, aminoglycosides, or amino acids served as substrates for BmiAANAT3. This suggests that positioning of the primary amine in an optimal configuration for
nucleophilic attack is critical for catalysis.
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Interestingly, acetyl-CoA displayed the highest Km,app value of the assayed short-chain
CoA substrates at 90 ± 3.6 µM. The other four CoAs exhibited nearly identical Km,app values of
10 to 14 µM (Table 2.10). As was the case with Bm-iAANAT, catalysis decreased with
increased acyl CoA chain length: acetyl-CoA exhibited a (kcat/Km)acyl-CoA,app 170x greater than
decanoyl-CoA, the longest coenzyme A substrate that demonstrated appreciable enzymatic rates.

Table 2.10 Apparent steady-state kinetic constants of Bm-iAANAT3 when tryptamine was held
constant at 8 mM and the acyl-CoA substrate concentration was varied.
Acyl-CoA

Chain
Length

Km, app
(μM)

kcat, app
(s-1)

(kcat/Km)app
(M-1 s-1)

Relative
(kcat/Km)app

Acetyl

2:0

90 ± 3.6

64 ± 0.74

(7.1 ± 0.3) x 105

170

Butyrl

4:0

14 ± 0.75

4.0 ± 0.04

(2.9 ± 0.2) x 105

70

Hexanoyl

6:0

13 ± 0.54

1.3 ± 0.01

(9.5 ± 0.4) x 104

23

Octanoyl

8:0

10 ± 1.0

0.36 ± 0.005

(3.4 ± 0.3) x 104

8.1

Decanoyl

10:0

12 ± 5.5

0.05 ± 0.004

(4.2 ± 1.9) x 103

1.0

2.3.3 Product Characterization of the Bm-iAANAT-Catalyzed Reaction
After discovering that Bm-iAANAT catalyzed the formation of long-chain Nacylarylalkylamides via our substrate screening assay, we set out to confirm the predicted Nacylamide product from an in vitro reaction mixture by high resolution mass spectrometry. We
assayed a synthesized N-oleoyltryptamine standard against the N-acylamide product of the
reaction mixture described in section 2.2.6, and compared the retention times and m/z values of
the [M+H]+ peak using LC/QTOF-MS. The findings corroborated our kinetic data: the Noleoyltryptamine produced from the Bm-iAANAT-catalyzed reaction is consistent for the
[M+H]+ peak and retention time (± 0.1 reported error for the LC/QTOF-MS) versus our
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synthesized standard N-oleoyltryptamine (Table 2.11). We did not detect N-oleoyltryptamine in
the no enzyme-containing (blank) samples. Further work will be conducted to confirm the
formation of the other previously identified long-chain N-acylarylalkylamides with this
technique.

Table 2.11 Product characterization of the Bm-iAANAT-catalyzed reaction via LC/QTOF-MS
analysis.
Sample

Retention Time (min) [M+H]+ (m/z)

N-oleoyltryptamine Standard

6.489

425.2588

Bm-iAANAT product

6.503

425.2574

2.3.4 Kinetic Mechanism of Bm-iAANAT3
We utilized several different enzymatic experiments to deduce the kinetic mechanism of
Bm-iAANAT3. First we constructed double reciprocal plots of initial velocities of acetyl-CoA
and tryptamine, while holding the other substrate at a fixed concentration. The resulting plots
(Figure 2.3) display intersecting lines for both substrates, indicative of a sequential mechanism
where both tryptamine and acetyl-CoA must be bound to the enzyme to form a ternary complex.
Only then can catalysis proceed. This is in contrast to the classical ping-pong mechanism, where
the first substrate binds and releases the first product (forming a metastable intermediate) before
binding of the second substrate occurs. The initial velocities were also subjected to global nonlinear regression analysis, in which several mechanistic models for a Bi-Bi system were
examined in a model discrimination analysis. The model discrimination also best supported a
steady-state ordered mechanism.
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Figure 2.3 Bm-iAANAT3 double-reciprocal analysis of initial velocities for acetyl-CoA and
tryptamine, fit to equation 2.3 in a global non-linear regression analysis. (A) Velocities
measured at fixed concentrations of tryptamine: 500 µM (), 250 µM (), 100 µM (), and 50
µM (). (B) Velocities measured at fixed concentrations of acetyl-CoA: 450 µM (), 225 µM
(), 90 µM (), and 45 µM ().

To distinguish between an ordered or random sequential mechanism, we employed
inhibition studies. Oleoyl-CoA and tyrosol were exploited as dead-end inhibitors against acetylCoA and tryptamine, respectively. Neither analog exhibited a rate of reaction above the baseline
rate of hydrolysis, and both have been previously utilized as dead-end inhibitors for the kinetic
mechanism determinations of D. melanogaster AANATs[14, 22] and mammalian serotonin Nacetyltransferase (SNAT).[23] Oleoyl-CoA was shown to be a competitive inhibitor versus
acetyl-CoA (Figure 2.4A) and a pure noncompetitive inhibitor against tryptamine (Figure 2.4B)
with inhibition constants of 220 ± 20 μM and 790 ± 30 μM, respectively. Tyrosol displayed
uncompetitive inhibition versus acetyl-CoA (Figure 2.4C) and was shown to be a competitive
inhibitor against tryptamine (Figure 2.4D), with inhibition constants of 230 ± 10 μM and 90 ± 10
μM, respectively. These inhibition patterns indicate the generation of N-acetyltryptamine
catalyzed by Bm-iAANAT3 follows an ordered sequential mechanism, with acetyl-CoA binding
49

first followed by tryptamine to form a ternary complex (Bm-iAANAT3•acetyl-CoA•tryptamine)
before catalysis can transpire. A similar kinetic mechanism was elucidated for sheep SNAT[24]
and several D. melanogaster AANATs.[14, 22]

Figure 2.4 Dead-end inhibition plots for Bm-iAANAT3. (A) Velocities measured at a fixed
concentration of tryptamine (100 µM) with varied concentrations of acetyl-CoA (10 µM, 25 µM, 50 µM,
and 100 µM), at varied concentrations of the inhibitor, oleoyl-CoA: 0 nM (), 250 nM (), and 500 nM
(); Ki = 220 ± 20 μM (B) Velocities measured at a fixed concentration of acetyl-CoA (100 µM) with
varied concentrations of tryptamine (50 µM, 100 µM, 150 µM, and 300 µM), at varied concentrations of
the inhibitor, oleoyl-CoA: 0 nM (), 250 nM (), and 500 nM (), Ki = 790 ± 30 μM (C) Velocities
measured at a fixed concentration of tryptamine (100 µM) with varied concentrations of acetyl-CoA (10
µM, 25 µM, 50 µM, and 100 µM), at varied concentrations of the inhibitor, tyrosol: 0 µM (), 150 µM
(), and 300 µM (); Ki = 230 ± 10 μM (D) Velocities measured at a fixed concentration of acetyl-CoA
(100 µM) with varied concentrations of tryptamine (50 µM, 100 µM, 150 µM, and 300 µM), at varied
concentrations of the inhibitor, tyrosol: 0 µM (), 150 µM (), and 300 µM (); Ki = 90 ± 10 μM
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Following our inhibition studies, we assayed the pH-dependence on the kinetic constants
of Bm-iAANAT3 for acetyl-CoA to determine the apparent pKa of the catalytic amino acid
residues. Both the kcat,app and (kcat/Km)app pH-rate profiles exhibited a rising conformation with
pKa,app values of 6.9 ± 0.2 and 6.7 ± 0.1, respectively (Figure 2.5)

Figure 2.5 pH rate profiles for Bm-iAANAT3. (A) log kcat versus pH for acetyl-CoA. (B) log
(kcat/Km) versus pH for acetyl-CoA.

An apparent pKa of ~6.8 can be ascribed to a general base in catalysis. This pKa value likely
corresponds to the general base deprotonating the primary amine of tryptamine; alternatively, it
could be attributed to the zwitterionic tetrahedral intermediate that is produced after the
nucleophilic attack of the acetyl-CoA thioester by tryptamine. This experiment did not explicate
a second, higher pKa value; this additional pKa (~8.5 – 10.0) would correspond to a general acid
in catalysis, routinely observed for NAT enzymes.[13, 22, 25] We hypothesize that Bm-iAANAT3
either lacks a general acid in catalysis, or the general acid has a pKa value > 9.5, a number too
high for us to ascertain due to limitations of acetyl-CoA hydrolysis and/or DTNB instability at
elevated pH ranges.
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Finally, in order to implicate catalytically-relevant amino acid residues, we produced a
site-directed alanine mutant of Glu-27, the probable general base in catalysis. This glutamate
residue is highly conserved in insect AANAT enzymes (as illustrated in the second row of the
homology overlay in Figure 2.2), and has been proposed as the general base in several
mechanistic studies.[14, 22] The E27A mutant enzyme was cultured, purified, and characterized in
the same manner as the wild-type Bm-iAANAT3. When assayed, this mutant only maintained
0.06% to 0.13% the kcat,app value compared to wild-type, in addition to exhibiting a 100-fold
increase in the Km,app for tryptamine (Table 2.12). The massive decline in catalytic activity as
compared to wild-type Bm-iAANAT3, in addition to the large perturbation in the (Km,tryptamine)app,
suggests that this residue functions as a general base in catalysis, as well as playing a role in
substrate binding. Glu-27 likely represents the pKa,app value of 6.8 observed in the pH-rate
profile (Figure 2.5)

Table 2.12 Steady-state kinetic constants for the E27A Bm-iAANAT3 mutant.
Acetyl-CoA
Enzyme

Km, app
(μM)

kcat, app
(s-1)

(kcat/Km)app
(M-1 s-1)

% Enzyme
Activity

Wild-Type

90 ± 3.6

64 ± 1.0

(7.1 ± 0.3) x 105

100

E27A

20 ± 2.2

0.04 ± 0.0009

(2.0 ± 0.2) x 103

0.28

Tryptamine
Enzyme

Km, app
(μM)

kcat, app
(s-1)

(kcat/Km)app
(M-1 s-1)

% Enzyme
Activity

Wild-Type

97 ± 8.8

60 ± 1.2

(6.2 ± 0.6) x 105

100

E27A

9400 ± 990

0.08 ± 0.003

8.8 ± 1.0

0.0014
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When taken together, our data strongly supports the mechanism depicted in Figure 2.6.
The double-reciprocal plots and dead-end inhibition analysis indicate an ordered sequential
mechanism: acetyl-CoA binds first, followed by tryptamine, thus forming a ternary complex
(Bm-iAANAT3•acetyl-CoA•tryptamine) before catalysis occurs. Once both substrates are bound
to the active site, a general base (Glu-27) deprotonates the positively charged amine moiety of
tryptamine through ordered water molecules, with subsequent nucleophilic attack on the
carbonyl of the acetyl-CoA thioester. This forms a zwitterionic tetrahedral intermediate, which
collapses as the coenzyme A thiolate is protonated by the positively charged amine of the
intermediate. We propose an ordered product release, with N-acetyltryptamine first exiting,
followed by coenzyme A. Future experimentation with ITC or intrinsic tryptophan fluorescence
testing the direct binding affinity of the free SH-CoA to Bm-iAANAT3 in the presence and
absence of N-acetyltryptamine should confirm this hypothesis. This mechanism is consistent
with other previously studied AANAT kinetic mechanisms.[14, 26]

Figure 2.6 Proposed mechanism for the N-acetylation of tryptamine by Bm-iAANAT3.
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2.4 Discussion and Conclusions
Understanding AANAT enzymes is of great scientific and economical importance. In
this study, we have successfully cloned, expressed, and purified a pair of AANAT enzymes from
Bombyx mori, and discovered several novel substrates for each. Notably, we have identified the
facility of Bm-iAANAT to catalyze the conjugation of long-chain N-acylarylalkylamides, only
the second enzyme of its kind ascertained to date (the first being Dm-AANATL2).[16] BmiAANAT may be the biological source of these potent neurotransmitters in vivo, while the
second enzyme we studied could be responsible for the inactivation of the biogenic amines in B.
mori. Bm-iAANAT3, a previously unstudied enzyme, displayed broad substrate specificity with
catalytic rates approaching 600x that of Bm-iAANAT. For this reason, we postulate BmiAANAT3 may play a greater role in regards to acetylating the arylalkylamides, while BmiAANAT is a versatile, multifaceted “generalist” enzyme in the silkworm. Bm-iAANAT is
capable of acylating a broad range of amines with either short or long-chain acyl-CoAs, while
Bm-iAANAT3 inactivates amines in a limited capacity, albeit in a far more potent manner.
In addition to our kinetic investigations into these AANAT enzymes, we have also begun
crystallography and inhibition studies (data not shown; pending publication). Due to the role of
AANAT in insect sclerotization, circadian entrainment, melanism, monoamine catabolism, and
melatonin production, it could prove to be an ideal target for the development of insecticides for
pest management. Several groups have successfully produced recombinant iAANAT variants
and screened them against chemical libraries to deduce compounds of high inhibitory affects.
Several were identified by the Tsugehara group that registered as herbicidal and miticidal agents,
acting as an acetyl-CoA carboxylase inhibitor and cuticle-penetrating toxin, respectively.[12, 27]
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Neither of these compounds displayed inhibition against sheep AANAT, proof positive that the
iAANAT enzymes share little homology with their mammalian counterparts.
Another intriguing possibility for pest control is the utilization of specific wavelengths of
light. For instance, it was demonstrated that the two spotted spider mite will avoid UV-blue
light.[6] The illumination of the mite to short-wave light affects mortality through increased ROS
damage (less production of the ROS scavenger melatonin) while disrupting cuticle formation, the
rate of oviposition, the inability to detoxify monoamine neurotransmitters, and photoperiodism.
If these compounds ultimately inhibit vertebrate AANAT enzymes, they could be utilized as
drugs that modulate endocrine function, sleep disorders, regulate mood and behavior through
pineal melatonin biosynthesis, and could also be used to improve vision by promoting the
detoxification of amines in the retina.[27-30]
We have also made great strides with crystallography studies, with a pending publication
regarding the crystal structure of Dm-AANATL8 from D. melanogaster. Our hope is that we
can not only gain a better understanding of the amino acids implicated in enzymology (which
will in turn lead to a better understanding of the AANAT-catalyzed mechanism), but to also
begin docking studies. We hope to elucidate tight binding bisubstrate analogs that could serve as
a platform for the creation of new activity based probes (ABP). Since there is little conserved
homology in the sequences of these enzymes from different organisms, we could use these
probes to enrich previously undiscovered mammalian AANAT orthologs. The study of these
novel enzymes would have vast implications for furthering the understanding of the human
brain, and the proteins and neurotransmitters that dictate a plethora of biophysical processes.
Our lab has extensive experience with the design and implantation of ABPP probes, which is the
focus of the work in Chapter 3.
55

2.5 References
[1]

Klein, D. C.; Weller, J. L., Indole Metabolism in Pineal Gland - A Circadian Rhythm in
N-acetyltransferase. Science 1970, 169 (3950), 1093-&.

[2]

Axelrod, J., The Pineal Gland: A Neurochemical Transducer. Science 1974, 184 (4144),
1341-1348.

[3]

Ebisawa, T.; Deguchi, T., Structure and restriction fragment length polymorphism of
genes for human liver arylamine N-acetyltransferases. Biochemical and Biophysical
Research Communications 1991, 177 (3), 1252-1257.

[4]

Chong, N. W.; Bernard, M.; Klein, D. C., Characterization of the chicken serotonin Nacetyltransferase gene - Activation via clock gene heterodimer/e box interaction. Journal
of Biological Chemistry 2000, 275 (42), 32991-32998.

[5]

Iuvone, P. M.; Tosini, G.; Pozdeyev, N.; Haque, R.; Klein, D. C.; Chaurasia, S. S.,
Circadian clocks, clock networks, arylalkylarnine N-acetyltransferase, and melatonin in
the retina. Prog. Retin. Eye Res. 2005, 24 (4), 433-456.

[6]

Hiragaki, S.; Suzuki, T.; Mohamed, A. A. M.; Takeda, M., Structures and functions of
insect arylalkylamine N-acetyltransferase (iaaNAT); a key enzyme for physiological and
behavioral switch in arthropods. Frontiers in Physiology 2015, 6.

[7]

Itoh, M. T.; Hattori, A.; Nomura, T.; Sumi, Y.; Suzuki, T., Melatonin and Arylalkylamine
N-acetyltransferase Activity in the Silkworm, Bombyx mori. Mol. Cell. Endocrinol.
1995, 115 (1), 59-64.

[8]

Josthna, P.; Mohan, P. M., Monoamine levels in the central nervous system and
haemolymph during 5th instar of the silkworm Bombyx mori L. J. Adv. Zool. 2002, 23
(1), 17-22.
56

[9]

Dai, F. Y.; Qiao, L.; Tong, X. L.; Cao, C.; Chen, P.; Chen, J.; Lu, C.; Xiang, Z. H.,
Mutations of an Arylalkylamine-N-acetyltransferase, Bm-iAANAT, Are Responsible for
Silkworm Melanism Mutant. Journal of Biological Chemistry 2010, 285 (25), 1955319560.

[10]

Zhan, S. A.; Guo, Q. H.; Li, M. H.; Li, M. W.; Li, J. Y.; Miao, X. X.; Huang, Y. P.,
Disruption of an N-acetyltransferase gene in the silkworm reveals a novel role in
pigmentation. Development 2010, 137 (23), 4083-4090.

[11]

Osanai-Futahashi, M.; Ohde, T.; Hirata, J.; Uchino, K.; Futahashi, R.; Tamura, T.; Niimi,
T.; Sezutsu, H., A visible dominant marker for insect transgenesis. Nat. Commun. 2012,
3.

[12]

Tsugehara, T.; Iwai, S.; Fujiwara, Y.; Mita, K.; Takeda, M., Cloning and characterization
of insect arylalkylamine N-acetyltransferase from Bombyx mori. Comp. Biochem.
Physiol. B-Biochem. Mol. Biol. 2007, 147 (3), 358-366.

[13]

Vetting, M. W.; de Carvalho, L. P. S.; Yu, M.; Hegde, S. S.; Magnet, S.; Roderick, S. L.;
Blanchard, J. S., Structure and functions of the GNAT superfamily of acetyltransferases.
Arch. Biochem. Biophys. 2005, 433 (1), 212-226.

[14]

Dempsey, D. R.; Jeffries, K. A.; Bond, J. D.; Carpenter, A.-M.; Rodriguez-Ospina, S.;
Breydo, L.; Caswell, K. K.; Merkler, D. J., Mechanistic and Structural Analysis of
Drosophila melanogaster Arylalkylamine N-Acetyltransferases. Biochemistry 2014, 53
(49), 7777-7793.

[15]

Long, Y.; Li, J.; Zhao, T.; Li, G.; Zhu, Y., A New Arylalkylamine N-Acetyltransferase in
Silkworm (Bombyx mori) Affects Integument Pigmentation. Appl Biochem Biotechnol
2015, 175 (7), 3447-3457.
57

[16]

Dempsey, D. R.; Jeffries, K. A.; Anderson, R. L.; Carpenter, A. M.; Opsina, S. R.;
Merkler, D. J., Identification of an arylalkylamine N-acyltransferase from Drosophila
melanogaster that catalyzes the formation of long-chain N-acylserotonins. FEBS Lett.
2014, 588 (4), 594-599.

[17]

Barrante, J. R., Applied Mathematics for Physical Chemistry (Third Edition). 2004.

[18]

Ho, S. N.; Hunt, H. D.; Horton, R. M.; Pullen, J. K.; Pease, L. R., Site-Directed
Mutagenesis by Overlap Extension Using the Polymerase Chain-Reaction. Gene 1989, 77
(1), 51-59.

[19]

Dempsey, D. R.; Bond, J. D.; Carpenter, A.-M.; Ospina, S. R.; Merkler, D. J.,
Expression, purification, and characterization of mouse glycine N-acyltransferase in
Escherichia coli. Protein Expression and Purification 2014, 97, 23-28.

[20]

Ferry, G.; Ubeaud, C.; Dauly, C.; Mozo, J.; Guillard, S.; Berger, S.; Jimenez, S.; Scoul,
C.; Leclerc, G.; Yous, S.; Delagrange, P.; Boutin, J. A., Purification of the recombinant
human serotonin N-acetyltransferase (EC 2.3.1.87): further characterization of and
comparison with AANAT from other species. Protein Expression and Purification 2004,
38 (1), 84-98.

[21]

Waluk, D. P.; Battistini, M. R.; Dempsey, D. R.; Farrell, E. K.; Jeffries, K. A.; Mitchell,
P.; Hernandez, L. W.; McBride, J. C.; Merkler, D. J.; Hunt, M. C., Mammalian Fatty
Acid Amides of the Brain and CNS. 2014; p 87-107.

58

[22]

Dempsey, D. R.; Jeffries, K. A.; Handa, S.; Carpenter, A. M.; Rodriguez-Ospina, S.;
Breydo, L.; Merkler, D. J., Mechanistic and Structural Analysis of a Drosophila
melanogaster Enzyme, Arylalkylamine N-Acetyltransferase Like 7, an Enzyme That
Catalyzes the Formation of N-Acetylarylalkylamides and N-Acetylhistamine.
Biochemistry 2015, 54 (16), 2644-2658.

[23]

Ferry, G.; Loynel, A. M.; Kucharczyk, N.; Bertin, S.; Rodriguez, M.; Delagrange, P.;
Galizzi, J. P.; Jacoby, E.; Volland, J. P.; Lesieur, D.; Renard, P.; Canet, E.; Fauchere, J.
L.; Boutin, J. A., Substrate specificity and inhibition studies of human serotonin Nacetyltransferase. Journal of Biological Chemistry 2000, 275 (12), 8794-8805.

[24]

De Angelis, J.; Gastel, J.; Klein, D. C.; Cole, P. A., Kinetic analysis of the catalytic
mechanism of serotonin N-acetyltransferase (EC 2.3.1.87). Journal of Biological
Chemistry 1998, 273 (5), 3045-3050.

[25]

Scheibner, K. A.; De Angelis, J.; Burley, S. K.; Cole, P. A., Investigation of the roles of
catalytic residues in serotonin N-acetyltransferase. Journal of Biological Chemistry 2002,
277 (20), 18118-18126.

[26]

Thoden, J. B.; Holden, H. M., Molecular Structure of WlbB, a Bacterial NAcetyltransferase Involved in the Biosynthesis of 2,3-Diacetamido-2,3-dideoxy-Dmannuronic Acid. Biochemistry 2010, 49 (22), 4644-4653.

[27]

Tsugehara, T.; Imai, T.; Takeda, M., Characterization of arylalkylamine Nacetyltransferase from silkmoth (Antheraea pernyi) and pesticidal drug design based on
the baculovirus-expressed enzyme. Comparative Biochemistry and Physiology Part C:
Toxicology & Pharmacology 2013, 157 (1), 93-102.

59

[28]

Khalil, E. M.; Cole, P. A., A Potent Inhibitor of the Melatonin Rhythm Enzyme. Journal
of the American Chemical Society 1998, 120 (24), 6195-6196.

[29]

Khalil, E. M.; De Angelis, J.; Ishii, M.; Cole, P. A., Mechanism-based inhibition of the
melatonin rhythm enzyme: Pharmacologic exploitation of active site functional plasticity.
Proceedings of the National Academy of Sciences of the United States of America 1999,
96 (22), 12418-12423.

[30]

Szewczuk, L. M.; Saldanha, S. A.; Ganguly, S.; Bowers, E. M.; Javoroncov, M.;
Karanam, B.; Culhane, J. C.; Holbert, M. A.; Klein, D. C.; Abagyan, R.; Cole, P. A., De
novo Discovery of Serotonin N-acetyltransferase Inhibitors. Journal of Medicinal
Chemistry 2007, 50 (22), 5330-5338.

60

CHAPTER THREE:
A FACILE, MICROWAVE-ASSISTED SYNTHESIS OF AN ADENOSINE-RIBOSE
PROBE FOR BINDING-BASED PROFILING OF NUCLEOSIDE AND NUCLEOTIDEBINDING PROTEINS

3.1 The Profiling of AdoR-Binding Proteins with a Novel Binding-Based Probe
Since the advent of genome mapping and the accessibility of complete genomic
sequences for various model organisms, the field of proteomics emerged to develop and apply
methods for the analysis of large numbers of proteins expressed by these genes. Proteomics can
be defined as the qualitative and quantitative comparisons of the protein products of organisms
under different conditions or stresses.[1] Proteomic analysis is inherently difficult because the
varying amounts of proteins expressed at a given time fluctuate greatly within a cell. In addition,
many other factors can contribute to analytical difficulties such as low expression, the varying
chemical properties of different cell types, location of the proteins (membrane-bound,
cytoplasmic, etc), the presence of post-translational modifications, and a lack of propagation
techniques such as the polymerase chain reaction.[1]
One such pioneering technique to overcome these technical challenges is activity-based
protein profiling (ABPP) which uses small molecules known as ABPP probes that covalently
bind to the catalytic site of specific targeted proteins acquired from cells, tissues, and even entire
organisms. Typically, these ABPP probes possess a “chemical warhead” that modifies the target
protein by reacting with a catalytically relevant active site nucleophile or electrophile to provide
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a measure of enzyme activity. ABPP probes are also designed to incorporate a chemical handle
that facilitates the identification and/or the purification of probe-modified proteins.[2] The probebased purification/enrichment process allows for the screening and detection of low-abundant
proteins, and can be used in addition to subcellular fractionation.
Specific ABPP probes have targeted different enzyme classes found within complex
proteomic systems: proteases, phosphatases, glycosidases, hydrolases, metalloproteases, kinases,
oxidoreductases, and proteasomal subunits.[3-4] The work we detail here describes the
development and utilization of a binding-based proteomic profiling probe (BBPP) that enriches
proteins that bind the adenine nucleosides and nucleotides (known as adenine ribose derivatives,
or AdoRs). Adenine nucleosides and nucleotides are endogenous purines that play vital roles in
biological systems, including DNA and RNA biosynthesis, signaling molecules such as
adenosine or cyclic adenosine monophosphate (cAMP), and as components of the cellular energy
currency in the form of the mono-, di- and triphosphates of adenosine (AMP, ADP, and ATP).[5]
There are numerous proteins in the cell that bind AdoRs, with various AdoR derivatives acting as
enzyme substrates, products, intermediates, coenzymes, or even as allosteric activators and
inhibitors.[6] The AdoR-binding proteome is easily one of the largest (over half of the human
proteome binds some form of nucleotide),[7] with aberrant or defective expression of many of
these proteins and enzymes being correlated to different diseases. This indicates the AdoRbinding proteome is an excellent target for the study of ABPP and BBPP technology, leading to
the discovery of novel biomarkers for the early diagnosis and evaluation of biological disorders.
Previously published work from our lab entailed the conception and development of an
adenosine-based BBPP probe for the selective targeting of AdoR-binding proteins with
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alterations on the purine ring at the N6- and C8- positions, as opposed to the more common
derivatization

site

on

the

5’-hydroxl

of

the

ribose

sugar.[8]

This

probe,

N6-[6-

(biotinamido)hexyl]-8-azidoadenosine, is shown in Figure 3.1.

Figure 3.1 The N6-Biotinylated-8-azidoadenosine activity based probe.
This BBPP probe includes an adenosine moiety for targeting the AdoR-binding proteins,
a photo-activatable azide which covalently binds the protein when UV irradiated, and a biotin tag
used for isolation and detection of the probe-labeled proteins. However, synthesis of N6biotinylated-8-azido-adenosine is tedious: an 8-step synthetic protocol with an overall yield of
10-15%, including a preparative HPLC purification step for a synthetic intermediate and the
detailed monitoring of the azidoylation step by LC-MS.[8] We report here on a novel synthetic
protocol

utilizing

microwave

irradiation

to

simplify

the

preparation

of

N6-[6-

(biotinamido)hexyl]-8-azidoadenosine to better supply this probe for proteomic profiling
applications. Given an improved and less expensive route to N6-[6-(biotinamido)hexyl]-8azidoadenosine, we used this to interrogate the AdoR-binding proteome of several different
species of Bacillaceae. Members of the family Bacillaceae consist of gram-positive, rod-shaped
bacteria that are genotypically and phenotypically heterogeneous, with many capable of
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producing endospores. These bacteria represent microbes of high economic, medical, and
military importance, used to produce biofuels, biopesticides, bioweapons, and even probiotics.[9]

3.2 Materials and Methods
A bacterial-specific protease inhibitor cocktail (Sigma: P8465) and anti-biotin antibody
HRP conjugate were purchased from Sigma Aldrich. Monomeric avidin agarose, SuperSignal
West Pico Chemiluminescent Substrate, and CL-XPosure film were purchased from Thermo
Scientific. Bacillus subtilis (ATCC 6051), Bacillus stearothermophilus (Geobacillus
stearothermophilus ATCC 7953), and Bacillus globisporus (Sporosarcina globispora ATCC
23301) were all purchased from ATCC. Microwave irradiation experiments were conducted in
an Anton Paar microwave reactor (Monowave 300). All other reagents and supplies were of the
highest quality available from commercial suppliers.

3.2.1 Synthesis of the Activity Based Probe
3.2.1.1 Synthesis of Compound 4: 2-(acetoxymethyl)-5-(6-((6-aminohexyl)amino)-8-bromo-9Hpurin-9-yl)tetrahydrofuran-3,4-diyl diacetate
Compound 3 (2’,3’,5’)-triacetyl-8-bromoinonsine) was prepared from commercially
available inosine as described.

[8]

Compound 3 (500 mg, 1.06 mmol) and PyBroP (1.05 eq: 520

mg, 1.12 mmol) were reconstituted with dry dichloromethane (DCM) and 8 equivalents (1.48
mL) of N,N-diisopropylethylamine (Hünig's base or DIPEA), while maintaining dry conditions.
Reagents were transferred to a 30 mL microwave reaction vessel with appropriate stir bar,
capped, and reacted in the microwave for 5 minutes at 1200 RPM, 30 bar (435 PSI), and 120°C
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to

form

the

phosphonium

intermediate.

Immediately

after

cooling,

1,6-diaminohexane (4 eq: 490 mg, 4.31 mmol) was slowly injected into the solution, ensuring
complete transfer. The tube was re-capped and reacted in the microwave for an additional 10
minutes at 1200 RPM, 30 bar (435 PSI), and 120°C. After completion of microwave irradiation,
an equal amount of water was added and mixed well to resolubilize the precipitated amine 4.
The reaction solution was extracted 2-3 times in DCM and water. The DCM extract was
taken to dryness using a rotary evaporator. Crude amine 4 was redissolved in 2 mL of 50:50
water and methanol and purified by reverse-phase column chromatography (RP-HPLC) using an
Agilent Eclipse XDB-C18 column (5 m, 9.4 mm × 250 mm) on a Waters Prep LC 4000 system
interfaced with 996 photo-diode array detector.

Amine 4 was eluted at 52:48 A:B using a linear

gradient of A:B (70:30 to 0:100) over 40 min at a flow rate of 5.0 mL/min, where solvent A was
H2O and solvent B was acetonitrile. Fractions containing amine 4 were combined, the volume
reduced to ~5 mL using a rotor evaporator, and, lastly, the solvent completely removed by
lyophilization. 258 mg purified; 43% yield.
LC-MSD m/z observed: 571.1. 1H NMR (400 MHz, cdcl3) δ 10.92 (s, 2H), 8.25 (s, 2H), 6.33 –
6.28 (m, 1H), 6.05 (d, J = 4.4 Hz, 2H), 5.91 (t, J = 5.9 Hz, 2H), 4.51 – 4.27 (m, 6H), 3.69 – 3.64
(m, 19H), 3.42 (d, J = 7.3 Hz, 4H), 3.08 (d, J = 7.4 Hz, 19H), 2.94 – 2.89 (m, 7H), 2.16 (s, 4H),
2.12 (s, 6H), 2.07 (s, 6H), 2.01 (s, 8H), 1.92 (s, 7H), 1.80 – 1.76 (m, 1H), 1.66 (s, 4H), 1.59 (s,
3H), 1.43 (s, 3H), 1.42 (s, 2H), 1.39 (s, 4H).
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3.2.1.2 Synthesis of Compound 5: 2-(acetoxymethyl)-5-(6-((6-aminohexyl)amino)-8-azido-9Hpurin-9-yl)tetrahydrofuran-3,4-diyl diacetate
Amine 4 (156 mg, 0.27 mmol) was reconstituted with 1 mL dry dimethylformamide
(DMF) per 50 mg of starting material, to which was added 100 L of water containing 10
equivalents of NaN3 (178 mg). The reaction mixture was microwave irradiated for 10 minutes at
120°C, 1200 RPM and 30 bar (435 PSI) in a small reaction vessel. Product was extracted in
DCM and brine, which greatly helped disperse the water/DMF emulsion. Compound 5 was
purified by RP-HPLC, as described by Mahajan et al. [8] 120 mg purified; 72% yield.
LC-MSD m/z observed: 534.2. 1NMR is identical to compound 9.

3.2.1.3 Synthesis of Probe 7: N6-[6-(biotinamido)hexyl]-8-azidoadenosine
Methods for the biotinylation of compound 5 to yield compound 6 followed by
deprotection of 6’-hydroxyl for production of the desired BBPP probe 7 have been described
previously.[8]

3.2.2 Growth of Bacterial Cells for Use in BBPP Studies
Small aliquots of each lyophilized cell line were reconstituted in sterile tryptic soy broth
(TSB) and grown overnight at the optimal temperature to amass the required concentration of
cells needed for glycerol stocks. Bacillus subtilis was grown at 37°C for 24 hours, Geobacillus
stearothermophilus at 55°C for 48 hours, and Sporosarcina globispora at 15°C for 72 hours.
These stocks were then plated on agar to ensure viable growth and single-colony purity.
Genuine colonies were used to make overnight broth cultures. A 3-hour growth was initiated in
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fresh broth, and then each bacterial species was standardized to an optical density value (OD600)
of 0.05 in new flasks. OD600 readings were then taken every hour for 8 hours, then again after
24, 48 and 72 hours, and this data was used to generate bacteria-specific growth curves (OD600
vs. time, data not shown). Given the growth curves for each bacterial species, we used these data
to harvest the bacterial cells in the exponential phase to ensure standardization.
Large scale liquid cultures (100 mL) in media broth were grown to the exponential
phase, harvested by centrifugation, and washed once with PBS.

The cell pellets were

resuspended in cell lysis buffer containing 20 mM Tris HCl (pH 7.4), 2 mM MgCl 2•6H20, 1 mM
EDTA, 2 mM EGTA, 150 mM NaCl, 1.0% TX-100, 1 mM PMSF, and 10 µL bacterial protease
inhibitor cocktail (Sigma Aldrich: P8340) per 1 mL cell solution. 1 mL aliquots of cells were
dispensed into Eppendorf tubes, and 100 µg of 0.1 mm glass lysing beads were added to each.
Tubes were placed in a bead beater and shaken at 4°C for four 60 second cycles. The tubes
containing crude cellular lysates were centrifuged twice at 13,400 RPM for 10 minutes, saving
the supernatant.

These supernatant fractions constituted the soluble proteome from each

bacterial species, and were stored at -80°C until evaluated using our BBPP probe. Protein
concentrations were determined using the Bradford dye-binding assay.[10]

3.2.3 Enrichment of AdoR-Binding Proteins and Subsequent Qualitative Analysis via
SDS-PAGE and Western Blots
To qualitatively assess the AdoR-binding proteome of several bacterial cell lines, an
enrichment protocol was adopted from the work of Mahajan, et al.
from

the

cellular

lysates

of

B.

subtilis,

G.

[8]

The soluble proteomes

stearothermophilus,

and

S. globispora were irradiated with ultraviolet light (295 nm) in the presence of BBPP probe 7 for
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2 minutes with intermittent stirring, at a ratio of 200 µM probe per 1 mg of proteome solution.
The resultant mixture of proteins and [protein + probe] conjugates was subjected to monomericavidin column chromatography to first elute non-bound proteins with PBS buffer (proteins that
have not been tagged by the probe and, thus, are not likely members of the adenosine-binding
proteome). This elution fraction was designated as the “PBS Wash”. Next, weakly bound
proteins (and thus, probe-affixed proteins) were eluted with a 2 mM biotin buffer, which acts as a
competitive affinity-binding agent for the avidin stationary phase, and is referred to as the
“Biotin Wash” fraction. Finally, the column is washed with a 0.1 M glycine buffer (pH 2.8)
which alters the avidin structure, disrupting the interaction between avidin and biotin. This
elution fraction is referred to as the “Regeneration Wash”, and thus constitutes the majority of
the AdoR-binding proteome from the cell lysates. Similar fractions were combined and reduced
over 10 kDa filters, and subjected to SDS-PAGE analysis in duplicate. The protein profiles were
further characterized by qualitative Western blot analysis; the Western blots were incubated with
an anti-biotin HRP-conjugated antibody, so that only biotinylated proteins (tagged proteins)
would be detected.

The membrane was then developed using SuperSignal West Pico

Chemiluminescent Substrate and exposed to CL-Xposure film.

A full discussion of the

enrichment protocol is detailed in the work by Mahajan, et al.[8]

3.3 Experimental Results
3.3.1 Synthesis of the AdoR-Binding Probe
The precedent protocol for the synthesis of N6-[6-(biotinamido)hexyl]-8-azido-adenosine
(Figure 1) is outlined in the work by Mahajan et al.[8] Inosine, an adenosine analog, is used as the
starting material and is first protected at the hydroxyl positions on the ribose ring with acetic
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anhydride and 4-dimethylaminopyridine (DMAP) in anhydrous DCM to yield a triacetyl
derivative.[11-12] The C8-position of the purine ring is then brominated using a saturated bromine
solution in 10% sodium phosphate,[13] followed by subsequent chlorination using thionyl
chloride under reflux to produce the 6,8-dichloro derivative.[14] Selective substitution of the
linker group (N-Boc-1,6-diaminohexane) was introduced at the N6-position at 0°C, with roughly
20% of the reaction being aminated at the C8-position as a side product. Replacement of the
chlorine atom at C8 with azide was achieved by refluxing for 5 days with cesium azide (CsN3)
and trimethylsilane azide (TMS-N3) in a dioxane/water solution. Deprotection of the N-Boc
group was accomplished using trifluoroacetic acid in DCM at room temperature, with
subsequent biotinylation using EDCI/DMAP coupling. Finally, a selective mono-deprotection
was conducted on the acetyl group at the 5’-position in an ammonia/methanol solution at -40°C,
providing the final AdoR-binding BBPP probe. We avoided the complete deprotection of the
ribose hydroxyls because such a BBPP would result in the enrichment of too great a number of
proteins for effective analysis; hence, the protecting acetyl groups were left to decorate the 2’
and 3’-hydroxyl of the ribose ring in our final BBPP probe.
The most significant synthetic challenge in producing our desired BBPP probe is the disubstitution at the N6 and C8-positions of the purine. Typically, nucleophilic displacement of the
N6-halogen atom with an amine occurs via a SNAr mechanism, a reaction that requires the initial
formation of the dichloro derivative (see compound 4 in the work of Mahajan et al). To
overcome this obstacle, attempts to directly aminate the purine at the N6-position without a
halogen

leaving

group

were

pursued

using

the

coupling

reagent

(benzotriazol-1-

yloxy)tris(dimethylamino) phosphonium hexafluorophosphate (BOP, as depicted in Figure 3.2)
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in DMF and DIPEA, as detailed in the literature.[15] However, this synthesis was unsuccessful,
most likely due to the presence of the bromine substitution at the C8-position.

Figure 3.2 The coupling reagent BOP, initially used in attempts to directly aminate the AdoRbinding ABP.

Recent work by Ashton and coworkers was successful in this directed amination using
bromo-tris-pyrrolidino phosphoniumhexafluorophosphate (PyBroP) in place of BOP under
microwave conditions, during which the reaction would proceed solely through a phosphonium
intermediate to yield the desired N6-substituded nucleoside.[16] This reaction mechanism is
illustrated in Figure 3.3. The PyBroP- utilized synthetic protocol is also advantageous since it
alleviates the undesirable amination at the C8-position, eliminating a major side product that is
difficult to remove. The novel synthetic approach to synthesize the desired BBPP probe
(compound 7) using microwave irradiation is detailed in Figure 3.4.
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Figure 3.3 PyBroP and the mechanism of direct amination on the N6-position of a nucleoside
proceeding through a phosphonium intermediate.

Direct amination was first attempted using the linker moiety, N-Boc-1,6-diaminohexane.
While this protected amine provided sufficient yields of the desired product, its relatively high
cost limited the amount of bulk probe that could be synthesized. Using the less expensive
unprotected 1,6-diaminohexane as an alternative linker, we found that microwave-assisted
PyBroP amination was successful, yielding compound 4 (43% yield). Another advantage of
using 1,6-diaminohexane as the linker is a simpler synthetic strategy because its use eliminates
the amine deprotection step prior to biotinylation.
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Figure 3.4 The microwave-assisted synthetic protocol of the AdoR-binding ABP (probe 7). This
method allows for a reduced cost of synthesis and abbreviated reaction times.

Upon addition of the deprotected aminated linker chain, displacement of the bromine at
the C8-location with the photo-activatable azide was attempted to yield compound 5. Typically,
this is a straightforward synthesis, utilizing CsN3 and TMS-N3 under standard reflux conditions
in DMF for several days. However, the alternative linker with a primary amine posed problems;
the free amine serving as a nucleophile deprotected the ribose ring leading to several undesirable
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side products. Accordingly, we developed a new method to install the azide at C8 of ribose,
which would reduce the amount of time the amine could deprotect the BBPP probe and would
eliminate the use of the costly CsN3.
We proposed that microwave irradiation would, again, solve our problems in the desired
azidylation of C8. Azides are considered good nucleophiles and can readily displace halides;
however, the reaction is often very slow, and prolonged exposure to high heat under reflux can
result in the decomposition of the azide (or worse, an explosion). The acceleration of this
reaction can be achieved using microwave conditions, demonstrated by the several groups that
had considerable success using domestic microwave ovens to produce azido-compounds in
drastically reduced times in similar yields to conventional heating.[17-18] Building upon this work,
the azidylation reaction was optimized using DMF and NaN3. Compound 5 was successfully
synthesized in yields up to 72%, and after HPLC purification, was converted to compound 6 with
the same EDCI/DMAP coupling reaction as reported in the original synthetic protocol. Similar
yields were achieved in producing probe 7 using our new synthetic strategy incorporating
microwave irradiation in two steps, significantly reducing both the time and cost required to
synthesize the desired BBPP probe.

3.3.2 Western Blot Analysis of the AdoR-Binding Proteome
To demonstrate the utility of the AdoR-directed BBPP probe synthesized using the
strategy outlined here, we used probe 7 to generate profiles from three microorganisms:
Sporosarcina globispora (a psychrophile), Bacillus subtilis (a mesophile), and Geobacillus
stearothermophilus a (a thermophile) (Figure 3.5).
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Figure 3.5 The proteomic profiles of B. subtilis (mesophile) compared to two extremophiles, G.
stearothermophilus (thermophile) and S. globispora (psychrophile). SDS-PAGE analysis in
pane (a) and Western blots in pane (b). Their profiles are quite dissimilar, indicating they
achieve metabolism with different types and quantities of adenine and adenosine-binding
proteins.

The proteomic profiles resulting from our use of probe 7 were analyzed by SDS-PAGE in
two ways: total protein analysis by staining with Coomassie Brilliant Blue (Figure 3.5, panel A),
and Western blot analysis using an anti-biotin antibody (Figure 3.5, panel B). The molecular
weight markers are shown in Lane 1, while Lanes 2 through 4 constitute the PBS Wash fractions
representing the unbound, non-tagged proteins. This group of proteins are not observed by
Western analysis (Figure 3.5, panel B). These proteins largely represent the non-AdoR-binding
proteins and comprise the most abundant fraction of the soluble cellular proteome (~70-80% of
the total soluble cellular proteome). The Biotin Wash, Lanes 5 to 7, is composed of the protein
eluted with 2.0 mM biotin. The Regeneration Wash, Lanes 8 to 10, contains the proteins most
tightly bound to the avidin column and were only eluted using a pH 2.8 wash solution that
disrupts the avidin-biotin interaction and restores the ability of avidin to bind biotin. The
74

proteins found within both the Biotin Wash and Regeneration Wash are AdoR-binding proteins,
representing ~20-30% of the total soluble cellular proteome. The Biotin Wash possesses the
lowest percentage of total soluble cellular proteome, 5-10%. Note that our data are consistent
with a previous estimate that AdoR-binding proteins represent ~25% of the total cellular
proteome[8] and, intuitively, it seems logical that the Biotin Wash (AdoR-binding proteins with
relatively low affinity for biotin) would contain the smallest percentage of total soluble
proteome.
The patterns evident in panels A and B of Figure 3.5 demonstrate that our BBPP probe
works well to generate defined proteomic profiles for the comparison of AdoR-binding protein
profiles between different organisms. By extension to these data, our BBPP probe would prove
valuable in defining and comparing AdoR-binding proteins between other related samples,
including cell lines, tissues, and disease states. The data shown in Figure 3.5 hint at intriguing
differences between the microorganisms because we loaded the same amount of total protein
(10 g) in each lane. More detailed and quantitative studies performed by growing the different
bacteria in SILAC media, with subsequent proteomic analysis using high resolution mass
spectrometry, would allow us to completely “mine” the data revealed by our BBPP probe. Such
work is beyond the scope of the project detailed herein.

3.4 Conclusion
Binding-based proteomic profiling is a natural extension from activity-based proteomic
profiling and will aid in the identification of important non-enzyme proteins, including receptors,
regulatory proteins, and structural proteins. Critical to the success of BBPP is the design and
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synthesis of useful BBPP probes. We describe here an improved strategy for the synthesis of
BBPP probes based on adenosine and the adenylate nucleotides (AdoRs). Our synthetic scheme
incorporates microwave irradiation at two steps relative to a previous reportedly strategy[8]
yielding a streamlined and more cost efficient route to the desired BBPP probe, compound 7.
Use of the BBPP probe produced by our improved protocol yields distinctive proteomic profiles
that point towards differences in the profiles of AdoR-binding proteins between related
psychrophilic, mesophilic, and thermophilic bacteria (Figure 3.5). The proteomic profiles
reported herein in combination with those published earlier using the same BBPP probe
demonstrate that compound 7 is useful in defining proteomic profiles for the comparison AdoRbinding proteins between different, biologically relevant samples.
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CHAPTER FOUR:
MECHANISTIC BINDING INSIGHTS FOR 1-DEOXY-D-XYLULOSE-5-PHOSPHATE
SYNTHASE, THE ENZYME CATALYZING THE FIRST REACTION OF
ISOPRENOID BIOSYNTHESIS IN THE MALARIA-CAUSING PROTISTS,
PLASMODIUM FALCIPARUM AND PLASMODIUM VIVAX

4.1 The Threat of Malaria, Isoprenoid Biosynthesis, and the Non-Mevalonate Pathway

Malaria is a life-threatening, infectious disease caused by parasites of the genus
Plasmodium, transmitted through the bite of an infected female Anopheles mosquito. Malaria
afflicts nearly 100 countries worldwide, with estimates of 198 million cases in 2013, resulting in
584,000 deaths.[1] Malaria poses a risk to roughly half of the population on earth, and infections
are on the rise due to global warming, deforestation, and drug and insecticide resistance. [1-5] In
humans, malaria is caused by an infection by one of five Plasmodium species: P. falicparum, P.
vivax, P. ovale, P. malariae, and P. knowlesi. P. falciparum malaria, constituting approximately
75% of the reported cases, is the most deadly form of malaria; however, P. vivax malaria,
constituting approximately 20% of the reported cases, is serious and more widespread. [1, 6]
Isoprenoids (or terpenoids) constitute one of the largest classes of complex, biologicallyactive compounds, which serve diverse roles, functioning as cholesterol, hormones, fat-soluble
hormones, carotenoids, pigments, and chlorophyll. [7-9] Isoprene is a five-carbon skeleton that is
the precursor of all isoprenoids through rearrangement, cyclization, and oxidation.

[10]

Yet,

isoprene itself is not used for the production of isoprenoids in vivo; instead the biological forms
of isoprene are the two branched, phosphorylated five-carbon precursors, dimethylallyl
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pyrophosphate (DMAPP) and isopentyl pyrophosphate (IPP). For half a century, it was thought
that the sole biosynthetic pathway of isoprenoid production was via the mevalonate pathway. [11]
However, in 1996, Rohmer et al.[12] discovered that certain eubacteria, parasites, and several
plants produce isoprenoids from a mevalonate-independent pathway.

This non-mevalonate

(NMVA) biosynthetic route (also known as the 2-C-methyl-D-erythritol 4-phosphate [MEP]
pathway) produces DMAPP and IPP from a set of orthogonal enzymes nonexistent in higher
organisms and mammals. The NMVA pathway, therefore, represents a platform for the
development of novel antimalarials and antibiotics to aid the treatment of human disease. [12]
In Plasmodium parasites, as well as other organisms from the phylum Apicomplexa, the
NMVA pathway produces DMAPP and IPP over seven successive enzymatic reactions.

The

first committed step of the pathway is catalyzed by 1-deoxy-D-xyluose-5-phosphate
reductoisomerase (DXR), which involves the NADPH-dependent rearrangement and two
electron reduction of the linear 1-deoxy-D-xylulose-5-phosphate (DXP) to the branched-chain
isoprenoid precursor MEP. However, the enzyme catalyzing the first reaction of the pathway is
also an attractive target for inhibitor development, 1-deoxy-D-xylulose-5-phosphate synthase
(DXS). DXS catalyzes the condensation of pyruvate and D-glyceraldehyde-3-phosphate (GAP)
to produced CO2 and 1-deoxy-D-xylulose-5-phosphate (DXP), a reaction that is the rate-limiting
for the NMVA pathway in several organisms as well as the branch point for B vitamin and
isoprenoid biosynthesis.

[13]

DXS belongs to the family of enzymes that utilizes thiamine

pyrophosphate (TPP) as a co-factor, and shares high homology with human transketolase,
pyruvate dehydrogenase, and pyruvate decarboxylase.

[14-15]

Like these other TPP-dependent

enzymes, DXS catalyzes decarboxylation and carboligation chemistry: a two-carbon
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intermediate bound to TPP (hydroxyethyl-TPP) is condensed with an acceptor substrate (GAP)
via nucleophilic addition to generate a new carbon-carbon bond yielding DXP.
All TPP-dependent enzymes catalyze two successive half reactions.

[16]

The first step

involves the attack of an activated TPP ylide at the first substrate. [17] The next step could occur
via three distinct mechanisms. The most common is the classical ping-pong mechanism, in
which the first product is released, forming a metastable enzyme-intermediate complex. Product
formation follows after binding of the second substrate. Every TPP-dependent enzyme studied
to date follows this mechanism, and has also been proposed for DXS from E. coli and H.
influenza.

[18]

Another possibility for the second half reaction proceeds through an ordered

mechanism, where the first product can only be released after the second substrate is bound to
the active site. The first substrate binds tightly and essentially irreversibly, while the second
substrate can only bind to a pocket opened in the presence of the first substrate. Carbon dioxide
(CO2) trapping studies on R. capsulatus DXS performed by Eubanks and Poulter suggested an
ordered sequential kinetic mechanism.

[19]

The results of the experiment indicated that pyruvate

bound first and irreversibly, followed by binding of GAP to form a ternary complex, and, finally,
the release CO2 and DXP in that order. However, subsequent work demonstrating that DXS will
catalyze the conversion of pyruvate to acetolactate and CO2 at high pyruvate concentrations
suggests that the kinetic mechanism for R. capsulatus DXS is not sequential. [20-21]
The third potential mechanism that DXS could display is a random sequential
mechanism, in which binding of both substrates is reversible and independent. Brammer et al.[20,
22]

has proposed an unprecedented rapid equilibrium, random sequential mechanism for E. coli

DXS, which is in contrast to all known TPP-dependent enzymes to date. Binding of either
pyruvate or GAP is independent of the other, and GAP is required for the release of CO 2 and the
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formation of a kinetically competent ternary structure. They suggest formation of the lactyl-TPP
intermediate is the overall rate limiting step and it is maintained in a low-reactive state. GAP
binding induces a reorientation to provide the optimal dihedral angle for decarboxylation. [23]
We report, herein, on the successful production of recombinant, catalytically active forms
of Plasmodium falciparum DXS and Plasmodium vivax DXR. Similar to earlier work on the
expression of P. vivax DXS

[24]

and P. falciparum DXR,[25] the catalytically active forms of P.

falciparum DXS and P. vivax DXR have been truncated to their respective catalytic cores,
lacking the signaling and transit peptide for each of these enzymes. In addition to recombinant
P. falciparum DXS and P. vivax DXR, we also produced the truncated forms of P. vivax DXS
and P. falciparum DXR in E. coli by following publication protocols. Both P. falciparum and
P. vivax DXS enzymes were characterized via steady-state kinetic analyses, intrinsic tryptophan
fluorescence titrations, and dead-end inhibition studies employing a pair of pyruvate mimics.
DXS activity was measured using a DXR-dependent coupled assay, pairing P. falciparum DXS
with P. falciparum DXR or P. vivax DXS with P. vivax DXR. Our characterization of DXS
from two Plasmodium species points toward a random sequential kinetic mechanism, an
unexpected finding for TPP-dependent enzymes. This work fosters a deeper understanding of
the DXS-catalyzed reaction and will aid in the rational design of DXS inhibitors for the
treatment of malaria and other human diseases.

4.2 Experimental Procedures
4.2.1 Materials and General Methods
Unless otherwise noted, all reagents were obtained from commercial sources. BL21
(DE3) E. coli cells and the pET-28a (+) vector were purchased from Novagen.
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PfuUltra

High-Fidelity DNA polymerase was purchased from Agilent. BamHI, XhoI, NdeI, Antarctic
Phosphatase, and T4 DNA ligase were purchased from New England Biolabs. Kanamycin
monosulfate and IPTG were purchased from Gold Biotechnology.

Size exclusion

chromatography was performed on a GE Healthcare AKTAprime Plus FPLC, coupled to a
HiLoad 16/600 Superdex 200 pg column. Spectrophotometric analyses were performed on a
Cary 300 Bio UV-Visible spectrophotometer. Tryptophan fluorescence studies were performed
on a JASCO FP-8300 spectrofluorometer.

4.2.2 Cloning of the P. falciparum dxs and P. vivax dxr Genes Without Signal and Transit
Peptides
A synthetic, codon-optimized gene for P. falciparum dxs was purchased from Genscript.
P. falciparum dxs was designed with 5’-NdeI and 3’-XhoI restriction sites and synthesized into a
pUC57 vector. The full-length gene was excised from the pUC57 vector and cloned into the
NdeI and XhoI restriction sites of the pET-28a vector. Similarly, a P. vivax dxr codon-optimized
gene was also purchased from Genscript, with 5’-NdeI and 3’-BamHI restriction sites in a
pUC57 vector. P. vivax dxr was cloned into pET-28a using NdeI and BamHI restriction sites.
Truncated gene constructs were produced from the full length, codon-optimized genes
using PCR extraction to eliminate expression of the N-terminal signal and transit peptides of
both PfDXS and PvDXR. PfDXS-A, PfDXS-B, PfDXS-C, and PfDXS-D were produced with
deletions of 237, 286, 292, and 310 amino acids, respectively. PvDXR-E, PvDXR-F, and
PvDXR-G were constructed with 99, 106, and 110 amino acid deletions, respectively. The
cloning of PvDXS was described previously.[24] The cloning of PfDXR has also been previously
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described,[25] and this gene was generously donated by Dr. Nobutada Tanaka at Showa
University (Japan) for the use in this study.
4.2.3 Overexpression of Truncated DXS and DXR Proteins in E. coli
Truncated gene transcripts of DXS and DXR in pET-28a were transformed into E. coli
BL-21 (DE3) cells. A fresh colony of cells harboring either truncated Pfdxs-pET-28a or PvdxrpET-28a were inoculated at 37°C in LB broth containing 40 µg/mL kanamycin supplemented
with 0.8% glucose and 25 mM potassium phosphate (pH = 7.2). The cultures were grown until
the OD600 reached 0.3, then diluted 1:100. For the overexpression of PfDXS, cells were cultured
until the OD600 reached 0.6, the temperature reduced to 10°C, induced by the addition of
0.5 mM IPTG, and incubated overnight (12 hours) with continuous shaking. To produce PvDXR,
the temperature was dropped to 30°C after achieving an OD600 of 0.6, induction initiated with
1 mM IPTG, and overnight incubation. Cells were harvested by centrifugation, and the cell
pellets stored at -80°C. The expression of PvDXS[24] and PfDXR[25] were described previously.

4.2.4 Purification of DXS and DXR by Ni-NTA Affinity and Size-Exclusion
Chromatography
Cells were thawed on ice and all purification steps were performed at 4°C. Cell pellets (4
g) were resuspended in 20 mL of binding buffer supplemented with protease inhibitors: 20 mM
Tris pH 7.5, 500 mM NaCl, 20 mM imidazole, 10 mM b-mercaptoethanol (BME), 1 mM
phenylmethylsulfonyl fluoride (PMSF), 4 mg/mL leupeptin, 2 mg/mL pepstatin, and 43 mg of an
E. coli-specific protease inhibitor cocktail (Sigma P8465). The cells were lysed via sonication,
centrifuged at 16,000 x g for 20 minutes at 4°C, and the recombinant enzyme-containing soluble
lysate was retained.
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Purification of DXS and DXR was facilitated by the fusion of an N-terminal His6-tag to
the active, truncated enzymes. The supernatant was applied to a borosilicate glass column
(1.5 cm × 5 cm) containing 5 mL of nickel-nitrilotriacetic acid (Ni-NTA) resin equilibrated with
binding buffer. The non-bound proteins were first eluted with 5 column volumes (CVs) of
binding buffer, then with 20 CVs of wash buffer (20 mM Tris pH 7.5, 500 mM NaCl,
60 mM imidazole, and 10 mM BME) at a flow rate of 1 mL/minute. Tagged, recombinant
enzyme was eluted with 2 CVs of elution buffer (20 mM Tris pH 7.5, 500 mM NaCl, 250 mM
imidazole, 10 mM BME) and concentrated to <3 mL using an Amicon stirred ultrafiltration cell
in preparation for size exclusion chromatography (SEC). The concentrated sample was injected
onto an AKTAprime FPLC coupled to a 16/600 Superdex column equilibrated with 50 mM Tris
pH 7.5, 150 mM NaCl, and 10 mM BME. The flow rate for the SEC was set to 1 mL/min with a
maximum pressure of 0.5 mPa. The concentration of the enzyme-containing fractions was
determined using the Bradford assay and purity was assessed by a 10% SDS-PAGE gel
visualized with Coomassie Brilliant Blue stain. Fractions containing purified enzyme were
combined, glycerol added to a final concentration of 10% (w/v), and the aliquots were flash
frozen in liquid nitrogen with subsequent storage at -80°C.

4.2.5 Kinetic Analyses
DXS activity from both P. falciparum and P. vivax was measured spectrophotometrically
using DXR from its corresponding organism as a coupling enzyme as previously reported
with minor variations.

[26]

The concentration of D-GAP was determined enzymatically from

commercially available D,L-GAP using human GAPDH.

[21]

Throughout the manuscript, our

use of “GAP” refers to the concentration of D-GAP in the D,L-GAP mixture. Reaction mixtures
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containing 100 mM HEPES pH 7.0, 100 mM NaCl, 1.5 mM MgCl2, 1 mg/mL BSA, 1 mM TPP,
2 mM BME, 150 μM NADPH, GAP, and pyruvate were preincubated for 5 minutes at 37°C.
DXR was pipetted into the cuvette (0.2 mg/mL), 100 nM of DXS was added to initiate the
reaction, and the solution (750 L total volume) was vigorously mixed before initializing the
spectrophotometer software. Rates of NADPH consumption in the coupled step between DXS
and DXR were monitored spectrophotometrically at 340 nm for 2 minutes (extinction
coefficient of 6,220 M–1 cm–1 for NADPH). The rates of NADPH depletion were used to
calculate initial rates of DXP formation. The apparent kinetic constants were determined by
fitting the resulting data to equation 4.1 using SigmaPlot 12.0: vo represents initial velocity,
Vmax,app is the apparent maximal velocity, Km,app is the apparent Michaelis constant, and [S] is the
substrate concentration. Assays were performed in triplicate and the uncertainty for the kcat,app
and (kcat/Km)app values were calculated using equation 4.2, where σ is the standard error.[27]

Equation 4.1

vo =

Vmax,app [S]
K m,app + [S]

Equation 4.2

σy 2
x
x σx 2
σ ( ) = √( ) + ( )
y
y
x
y

To delineate between a sequential and classic ping-pong mechanism, double-reciprocal
plots of the initial velocity data were generated for GAP and pyruvate in SigmaPlot 12.0.
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Non-linear regression analysis of initial rates and model discrimination analyses were performed
in WaveMetrics IGOR Pro 6. Initial velocities were determined by varying the concentration of
one substrate, while holding the other substrate at a fixed concentration. GAP was evaluated
between 3.5 μM and 16 μM, whereas pyruvate was tested at concentrations ranging from 50 μM
to 250 μM. The resulting initial velocity data was fit to equation 4.3 for a rapid-equilibrium
random Bi-Bi mechanism, where vo is the initial velocity, Vmax is the maximal velocity, [A] is
the concentration of substrate A, [B] is the concentration of substrate B, Kia is the dissociation
constant for substrate A, Kb is the Michaelis constant for substrate B, and Ka is the Michaelis
constant for substrate A.

Equation 4.3

vo =

Vmax [A][B]
K ia K b + K a [B] + K b [A] + [A][B]

4.2.6 Synthesis of Methylacetylphosphonate (MAP)
MAP was synthesized, as previously reported,

[20, 28-30]

with minor variations. In a dry

three-necked round bottom flask with a magnetic stir bar under positive N2 pressure, acetyl
chloride (1.21 mL, 14 mmol, 1 eq) was cooled to 0°C in an ice-water bath. Trimethyl phosphite
(1.65 mL, 14 mmol, 1 eq) was slowly injected over a period of 3 hours, which resulted in
evolution of MeCl. After full addition of trimethyl phosphite, the light-grey solution was allowed
to warm to room temperature and stirred for an additional 8 hours. Unreacted reagents were
removed under vacuum to afford acetylphosphonate dimethyl ester (DAP). 1.58 g recovered
(10.4 mmol, 74% yield) as a pale grey oil. 1H NMR (400 MHz, CDCl3) δ 2.24 (d, J = 5.31 Hz,
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3H, CH3), 3.61 (d, J = 10.69, 6H, OCH3).

13

C NMR (400 MHz, CDCl3): d= 208.1

(d, JP,C=169.8 Hz), 54.0 (d, 2JP,C=7.2 Hz, 2 C), 20.9 (d, 2JP,C=36.0 Hz).
The recovered DAP (1.58 g, 10.4 mmol, 1 eq) was dissolved in dry acetone (10.4 mL),
and the solution was slowly injected into a solution of sodium iodide (1.71 g, 11.5 mmol, 1.1 eq)
in 6 mL dry acetone. The yellow reaction mixture was stirred overnight at room temperature
after which the precipitate was filtered, triturated with dry acetone, and dried to yield purified
MAP. 93% yield. 1H NMR (400 MHz, D20) δ 2.20 (3 H, d, J 9.8 Hz) and 3.69 (3 H, d, J 10.63
Hz). All NMR spectra of isolated compounds are in agreement with literature reports.

4.2.7 Inhibition of DXS with β-Fluorpyruvate and Methylacetylphosphonate
The varying inhibition patterns of DXS activity were measured with the DXS-DXR
coupled assay in the presence of either β-fluoropyruvate or methylacetylphosphonate (MAP).
Inhibitor concentrations were based upon previously established IC50 values (data not shown)
and added to the kinetic reaction mixtures described above. For PvDXS, the concentrations of
β-fluoropyruvate tested were 0, 35, and 75 μM, while MAP was analyzed at 0, 150, and 300 μM.
To test PfDXS inhibition, β-fluoropyruvate and MAP concentrations were held at 0, 50, 100 μM
and 0, 70, 140 μM, respectively. No inhibition of DXR by either inhibitor was observed. All
assays were performed in triplicate, and the resulting data was fit to equations 4.4 – 4.6 in
SigmaPlot 12.0 for competitive, noncompetitive, and uncompetitive inhibition, respectively. For
equations 4.4 – 4.6, vo is the initial velocity, Vmax,app is the apparent maximal velocity, Km,app is
the apparent Michaelis constant, [S] is the substrate concentration, [I] is the inhibitor
concentration, and Ki is the inhibition constant.
Equation 4.4
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vo =

Vmax,app [S]
[I]
K m,app (1 + K ) + [S]
i

Equation 4.5

vo =

Vmax,app [S]
[I]
[I]
K m,app (1 + K ) + [S] (1 + K )
i
i

Equation 4.6

vo =

Vmax,app [S]
[I]
K m,app + [S] (1 + K )
i

4.2.8 Intrinsic Tryptophan Fluorescence Measurements for the Determination of Binding
Constants for DXS
To study the binding of pyruvate and GAP to DXS, intrinsic tryptophan fluorescence
(ITF) quenching titrations were utilized. All reaction mixtures for ITF titrations contained 100
mM HEPES pH 7.0, 100 mM NaCl, 1.5 mM MgCl2, 2 mM BME, and 500 nM DXS in a final
volume of 400 L. Fluorescent emission spectra were acquired on a JASCO FP-8300
spectrofluorometer at 25°C. The excitation wavelength was set at 280 nm, and emission
occurred between 290-300 nm. Spectra were measured in triplicate from 305 nm to 360 nm,
using a scan speed of 50 nm/min, and both excitation and emission bandwidth set at 2.5 nm.
Spectra were corrected by subtracting emission spectra from acquisitions containing no enzyme
(blanks), and normalized by taking the ratio of the fluorescence intensity at the λmax relative to
starting enzyme only samples. Data were fit to equation 4.7, where ΔF is the change in intrinsic
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fluorescence, ΔFmax is the maximum change of fluorescence at infinite ligand concentration,
[L] is the ligand concentration, and Kd is the ligand dissociation constant.
Equation 4.7
∆F =

∆Fmax [L]
K d + [L]

4.3 Results and Discussion
Malaria parasites and other infectious organisms of the phylum Apicomplexa possess the
apicoplast, an endosymbiotic organelle similar to the chloroplast of plants and algae. [31] With a
complete genome producing nearly 400 assorted proteins, the apicoplast is vital in various
aspects of parasite metabolism including fatty acid and isoprenoid biosynthesis. All of the
enzymes from the non-mevalonate pathway are nuclear-encoded and translocated to the
apicoplast through a secretory pathway utilizing a bipartite N-terminal signaling motif. This
sequence consists of two functional domains: an endoplasmic reticulum-targeting signal peptide
and a transit peptide.

The signal peptide directs the translocation of the enzyme into the

secretory pathway, while the transit peptide facilitates the movement through the four outer
membranes of the apicoplast. Once inside, the peptides are cleaved off (most likely by a stromal
processing protease) to yield the catalytically-competent enzyme. [32]
To date, only a few enzymes targeted to the apicoplast from Plasmodium have been
expressed, due in part to difficulties in obtaining soluble recombinant enzyme from E. coli host
cells.

[24, 33-34]

In addition to codon biases between E. coli and Plasmodium species (high GC

content, ribosomal binding sites, random repeats of rare codons, etc), the presence of the
signaling and transit motifs consistently result in the accumulation of insoluble inclusion bodies.
[33]

Therefore, serial deletion of the full-length, untruncated gene is required to produce a DXS
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or DXR variant that is soluble when expressed in E. coli. Several freely available algorithms
(PlasmoAP [35], PATS [36], PSORT [37], etc.) have been developed, which have proven successful
in identifying the signal peptide. Note that the signal peptide varies in length from 20-30 amino
acids and exhibits a consensus sequence. In contrast, there is no consensus sequence or narrowly
defined size for the transit peptide, which can vary from 50-500 amino acids, meaning that there
are no current algorithms that can accurately predict this peptide region (see Figure 4.1 of the
DXS amino acid sequence from several organisms with low N-terminal homology). Malarial
transit peptides can be approximated by the presence of highly enriched lysine and asparagine
residues, which results in an overall positive charge.

[35]

This trend is pronounced in the amino

acid sequence of P. falciparum DXS between residues ~150-300 (Figure 4.1, note the high
number of successive asparagine residues).

Figure 4.1 Homology overlays of the N-terminal amino acid sequence for Plasmodium vivax,
Plasmodium knowlesi, Plasmodium cynomolgi and Plasmodium falciparum.
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By utilizing homology modeling and N-terminal serial deletions of the full-length codonoptimized genes, several targeted variants of PfDXS and PvDXR were produced in our
expression optimization study. PfDXS-A, PfDXS-B, PfDXS-C, and PfDXS-D were generated
with N-terminal deletions of 237, 286, 292, and 310 amino acids, respectively. PvDXR-E,
PvDXR-F, and PvDXR-G were constructed with N-terminal deletions of 99, 106, and 110 amino
acid deletions, respectively. Each of these genes was then transformed into BL-21 (DE3) E. coli
expression cells, and cultured in 2 mL aliquots. These small-scale cultures were optimized for
time of expression (1, 3, 5, and 12 hours), induction temperature (10, 25, 30, or 37°C) and IPTG
concentration (0.1, 0.5, or 1.0 mM) for a total of 48 culture conditions per truncated gene. The
small scale cultures were then centrifuged, lysed via sonication, and the soluble proteome
subjected to an anti-6His Western blot antibody assay for the detection of recombinant enzyme.
Only one truncated gene and one set of variables proved successful for each enzyme: PfDXS-D
(with 310 amino acids deleted) was expressed at 10°C, induced by the addition of 0.5 mM
isopropyl β-D-1-thiogalactopyranoside (IPTG), and incubated overnight (12 hours) with
continuous shaking. After subsequent purification via Ni-NTA affinity and size exclusion
chromatography, the final yield of PfDXS-D was 1.4 mg/L (Figure 4.2).
To produce PvDXR, the protein construct with 110 amino acids removed (PvDXR-G)
produced soluble enzyme at 30°C with 1 mM IPTG and overnight incubation. PvDXR-G
yielded 0.9 mg/L after both affinity and size exclusion chromatography (Figure 4.3). This
enzyme was used in the DXS-DXR coupled assay to further study PvDXS (kinetic constants of
PvDXR-G: Km = 48 ± 1.6 μM, Vmax = 1.3 ± 0.01 s-1, kcat/Km = (2.7 ± 0.1) x 104 M-1s-1. These
values are in good agreement with previously published data for DXR from several other
organisms.

[38-41]

The cloning, expression, and characterization of PfDXR
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[25]

and PvDXS

[24]

were previously described. From this point forth, PfDXS-D and PvDXR-G will simply be
referred to as PfDXS and PvDXR, respectively.

Figure 4.2 Purification scheme of Plasmodium falciparum DXS.
(A) Size-exclusion chromatography elution profile versus enzymatic activity.
(B) SDS-PAGE of the purification workflow
1) Molecular weight ladder
2) Nickel-column binding fraction
3) Nickel-column wash fraction
4) Nickel-column elution fraction
5) Size-exclusion column load
6) Size-exclusion column -purified PfDXS
7) MagicMark XP Western blot molecular weight ladder
(C) Western blot of the purification workflow
1) Molecular weight ladder
2) Nickel-column binding fraction
3) Nickel-column wash fraction
4) Nickel-column elution fraction
5) Size-exclusion column load
6) Size-exclusion column -purified PfDXS
7) MagicMark XP Western blot molecular weight ladder
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Figure 4.3 Purification scheme of Plasmodium vivax DXR.
(A) Same as A above
(B) Same as B above
(C) Same as C above

Once both sets of enzymes were cloned, expressed, and purified, we set about to
elucidate kinetic and binding characteristics of DXS from P. falciparum and P. vivax. For the
determination of kinetic constants, initial velocities of DXP formation were monitored using the
DXS-DXR coupled assay at sub-saturating concentrations of one substrate, while holding the
other fixed. Rates were determined in triplicate. Binding constants were obtained using intrinsic
tryptophan fluorescence titrations, and the results of both of these experiments are detailed in
Table 4.1.
The kinetic constants for both P. falciparum DXS and P. vivax DXS are comparable to
previously published data for DXS from E. coli, R. capsulatas, and D. radiodurans. The Kd
values for both Plasmodium enzymes are also commensurate with the dissociation constants for
E. coli DXS (see Figures 4.4 and 4.5). Clues of the binding mechanism can be delineated from
these data: in the ordered mechanism with pyruvate binding first and, irreversibly, binding of
pyruvate to DXS will induce a conformational change that promotes binding of GAP. Binding
of GAP to free enzyme should, therefore, be negligible.
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[20]

However, a measurable binding

constant for pyruvate to both PfDXS and PvDXS suggests that pyruvate binding is, in fact
reversible, inconsistent with an ordered mechanism. In the proposed ping-pong mechanism, GAP
will have low affinity for the free enzyme. However, again, we observed quenching of the
fluorescent signal indicative of GAP binding reversibly to both of the Plasmodium DXS
enzymes. These data are inconsistent with a ping-pong mechanism. Taken together, the ITF data
supports a random sequential mechanism where GAP and pyruvate can both bind reversibly and
independently to either P. falciparum or P. vivax DXS.
Also noted in our ITF data is an apparent Stokes shift in the wavelength for maximum
fluorescence intensity when DXS is incubated with high concentrations of GAP, which was not
found at similarly high levels of pyruvate (Figures 4.4 and 4.5). Tryptophan fluorescence is
commonly used to monitor perturbations in protein dynamics and localized structures;
fluorescence from tryptophan is sensitive to the polarity of its local environment.

[42]

Therefore,

this apparent Stokes shift suggests that GAP binding induces a conformation change in DXS, at
least within the vicinity of the fluorescent tryptophan residue. This represents the first report of a
conformational change in DXS upon substrate binding. Additional data for other DXS enzymes
is required to determine the significance of our observation.
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Table 4.1

Binding Constants and Steady-State Kinetic Constants of DXS from several organisms
Pyruvate
Organism

Km, app
(μM)

Kd (μM)

GAP

kcat, app
-1

(s )

(kcat/Km)app
-1 -1

(M s )
(6.5 ± 0.2) x

P. falciparum

640 ± 16

2600 ±
650

4.2 ± 0.03

P. vivax

1090 ± 60

770 ± 210

6.6 ± 0.15

E. coli

49 ± 8.0

230 ± 70

2.6 ± 0.11

5.3 x 10

R. capsulatus

440 ± 50

--

1.9 ± 0.10

4.3 x 10

D. radiodurans

280 ± 30

--

7.4 ± 0.30

2.6 x 10

10

(μM)

Kd (μM)

kcat, app
-1

(s )

(kcat/Km)app
-1 -1

(2.5 ± 0.4)

4100 ±
1200

4.1 ± 0.17

26 ± 2.6

2300 ±
1300

6.4 ± 0.22

4

24 ± 1.7

2000 ±
500

2.6 ± 0.11

1.1 × 10

3

68 ± 1.0

--

1.9 ± 0.10

2.8 × 10

4

50 ± 10.0

--

7.9 ± 0.40

1.5 × 10

3

Reference

(M s )

16 ± 2.3

3

(6.1 ± 0.4) x
10

Km, app

× 10

5

(2.4 ± 0.3)
× 10

5

1

1

5

2

4

3

5

4

References:
1. This study
2. Brammer, L. A.; Smith, J. M.; Wade, H.; Meyers, C. F., 1-Deoxy-D-xylulose 5-Phosphate Synthase Catalyzes a Novel
Random Sequential Mechanism. Journal of Biological Chemistry 2011, 286 (42), 36522-36531.
3. Eubanks, L. M.; Poulter, C. D., Rhodobacter capsulatus 1-deoxy-D-xylulose 5-phosphate synthase: Steady-state kinetics and
substrate binding. Biochemistry 2003, 42 (4), 1140-1149.
4. Handa, Sumit, "1-deoxy-D-xylulose-5-phosphate Synthase (DXS) Mechanistic Study and its Implication in the Development
of Novel Antibiotics and Antimalarials" (2012). Graduate Theses and Dissertations.
<http://scholarcommons.usf.edu/etd/4063>
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Figure 4.4 Substrate-binding analysis of PvDXS by intrinsic-tryptophan quenching titrations
with increasing [pyruvate] and [GAP].
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Figure 4.5 Substrate-binding analysis of PfDXS by intrinsic-tryptophan quenching titrations
with increasing [pyruvate] and [GAP].
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Double-reciprocal plots were generated to differentiate between a sequential binding
mechanism and a ping-pong mechanism for both of the DXS enzymes from Plasmodium
(Figures 4.6 and 4.7).

The Lineweaver-Burk plots for both GAP and pyruvate had

noncompetitive pattern with changes in both slope and intercept, suggesting a random sequential
mechanism. If substrate binding to DXS were ordered, a competitive pattern for GAP would
result and an uncompetitive pattern for pyruvate would be observed. Substrate inhibition was
found at higher concentrations of both pyruvate and GAP (as evidenced by the converging lines),
similar to what was reported by Brammer, et al.[20] for E. coli DXS. The data was further
evaluated using global non-linear regression analysis: several mechanistic models for a two
substrate, two product (Bi Bi) system were examined in a model discrimination analysis (rapidequilibrium ordered, rapid-equilibrium random, ping-pong, etc). The data were best fit to the
equations for a random sequential mechanism (Figures 4.8 and 4.9).
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Figure 4.6 PvDXS double-reciprocal plots of initial velocities for pyruvate and GAP.
(A) Velocities measured at fixed concentrations of GAP: 0.016 mM (), 0.008 mM (), 0.005
mM (), 0.0035 mM (). (B) Velocities measured at fixed concentrations of pyruvate: 0.25
mM (), 0.15 mM (), 0.10 mM (), and 0.05 mM ().

Figure 4.7 PfDXS double-reciprocal plots of initial velocities for pyruvate and GAP. (A)
Velocities measured at fixed concentrations of GAP: 0.016 mM (), 0.008 mM (), 0.005 mM
(), 0.0035 mM (). (B) Velocities measured at fixed concentrations of pyruvate: 0.25 mM
(), 0.15 mM (), 0.10 mM (), and 0.05 mM ().
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Figure 4.8 PvDXS global non-linear regression analysis for a random sequential mechanism.
Velocities measured at fixed concentrations of GAP: 0.016 mM (), 0.008 mM (), 0.005 mM
(), 0.0035 mM (). (B) Velocities measured at fixed concentrations of pyruvate: 0.25 mM
(), 0.15 mM (), 0.10 mM (), and 0.05 mM ().

Figure 4.9 PfDXS global non-linear regression analysis for a random sequential mechanism.
Velocities measured at fixed concentrations of GAP: 0.016 mM (), 0.008 mM (), 0.005 mM
(), 0.0035 mM (). (B) Velocities measured at fixed concentrations of pyruvate: 0.25 mM
(), 0.15 mM (), 0.10 mM (), and 0.05 mM ().

101

Finally, inhibition studies were conducted to further confirm the mechanism of substrate
binding to DXS. Both β-fluoropyruvate and MAP have been previously used as pyruvate
mimics to study TPP-dependent enzyme mechanisms.

[28, 43-45]

After TPP activation,

β-fluoropyruvate undergoes a catalytic step to release CO2 with consequent elimination of
fluoride; therefore, it is not representative of a true dead-end inhibitor against pyruvate. MAP
cannot undergo decaboxylation, and is, accordingly, a more suitable pyruvate analog.

[20]

Initial

rates of DXP production were monitored using the DXS-DXR coupled assay at sub-saturating,
varied concentrations of one substrate at fixed concentrations of the second substrate, in the
presence of either inhibitor at varied concentrations. The equations for competitive,
noncompetitive, and uncompetitive inhibition were fit to the data, and the results of the best fits
are shown in Figures 4.10 and 4.11.
fluoropyruvate

displayed

competitive

For the pair of DXS enzymes, both MAP and βinhibition

against

pyruvate,

while

exhibiting

noncompetitive inhibition versus GAP (Table 4.2). This pattern of results is most consistent
random sequential binding mechanism for both substrates to DXS. Conversely, a ping-pong
mechanism would yield an uncompetitive pattern with respect to GAP. Unfortunately, the
absence of a dead-end competitive inhibitor against GAP, precludes a definitive determination of
the kinetic mechanism for the Plasmodium DXS enzymes included in our study, an impediment
noted by several other groups. [19]
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Figure 4.10 Inhibition of DXS by β-fluoropyruvate. (A) PvDXS assayed with varied
concentrations of pyruvate at fixed concentrations of GAP (26 μM), in the presence of
β-fluoropyruvate: 0 μM (), 35 μM (), and 75 μM (). (B) PvDXS assayed with varied
concentrations of GAP at fixed concentrations of pyruvate (1.1 mM), in the presence of
β-fluoropyruvate: 0 μM (), 35 μM (), and 75 μM (). (C) PfDXS assayed with varied
concentrations of pyruvate at fixed concentrations of GAP (16 μM), in the presence of
β-fluoropyruvate: 0 μM (), 50 μM (), and 100 μM (). (D) PfDXS assayed with varied
concentrations of GAP at fixed concentrations of pyruvate (640 μM), in the presence of
β-fluoropyruvate: 0 μM (), 50 μM (), and 100 μM ().
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Figure 4.11 Inhibition of DXS by MAP. (A) PvDXS assayed with varied concentrations of
pyruvate at fixed concentrations of GAP (26 μM), in the presence of MAP: 0 μM (), 150 μM
(), and 300 μM (). (B) PvDXS assayed with varied concentrations of GAP at fixed
concentrations of pyruvate (1.1 mM), in the presence of MAP: 0 μM (), 150 μM (), and 300
μM (). (C) PfDXS assayed with varied concentrations of pyruvate at fixed concentrations of
GAP (16 μM), in the presence of MAP: 0 μM (), 70 μM (), and 140 μM (). (D) PfDXS
assayed with varied concentrations of GAP at fixed concentrations of pyruvate (640 μM), in the
presence of MAP: 0 μM (), 70 μM (), and 140 μM ().
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Table 4.2 Inhibition constants for β-fluoropyruvate and MAP against PvDXS and PfDXS

Enzyme

Inhibitor
β-fluoropyruvate

PvDXS
MAP
β-fluoropyruvate
PfDXS
MAP

Substrate
Pyruvate
GAP
Pyruvate
GAP
Pyruvate
GAP
Pyruvate
GAP

Pattern
Competitive
Noncompetitive
Competitive
Noncompetitive
Competitive
Noncompetitive
Competitive
Noncompetitive

Ki app(μM)
35 ± 1.7
77 ± 7.2
75 ± 5.0
89 ± 6.7
43 ± 3.8
131 ± 10
46 ± 3.8
103 ± 7.2

4.4 Conclusion
The first two enzymes of the non-mevalonate pathway in the malaria-causing protists
Plasmodium vivax and Plasmodium falciparum are DXS and DXR, respectively. Catalytically
active, truncated forms of all four enzymes have been cloned and over-expressed in E. coli:
P. falciparum DXS (described herein), P. falciparum DXR by Umeda et al.[25], P. vivax DXS by
Handa et al.[24], and P. vivax DXR (described herein). Because of the metabolic centrality of the
isoprenoids, the availability of DXS and DXR from P. falciparum and P. vivax should facilitate
the development of novel anti-malarials targeted against either of these enzymes. The kinetic
mechanism for DXS has proven controversial, with the majority of the published data pointing
towards a random sequential mechanism.

[20, 22]

Such a mechanism is unusual for a TPP-

dependent enzyme, as the first substrate typically forms an adduct with the thiazolium moiety of
TPP.

[16-17, 22]

yielding either an ordered or ping-pong kinetic mechanism. Our characterization

of PfDXS and PvDXS, steady-state kinetic analyses, substrate binding studies, and dead-end
inhibition experiments, are most consistent with a random sequential mechanism for both
enzymes. The expression of PfDXS and PvDXS in E. coli, providing straightforward access to
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multi-milligram amounts of protein and fostering the construction of site-directed mutants, will
enable the detailed structure-function studies to better understand the unique aspects of TPPdependent chemistry of DXS.
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APPENDIX A
Chapter 2 Supplementary Information

Figure A.1 Bm-AANAT with 100 μM oleoyl-CoA and varied tryptamine.
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Figure A.2 Bm-AANAT with 100 μM oleoyl-CoA and varied octopamine.

Figure A.3 Bm-AANAT with 100 μM oleoyl-CoA and varied tyramine.
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Figure A.4 Bm-AANAT with 100 μM lauroyl-CoA and varied tryptamine.

Figure A.5 Bm-AANAT with 100 μM myristoyl-CoA and varied tryptamine.
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Figure A.6 Bm-AANAT with 100 μM palmitoyl-CoA and varied tryptamine.

Figure A.7 Bm-AANAT with 60 mM tryptamine and varied arachidonoyl-CoA.
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Figure A.8 Bm-AANAT with 60 mM tryptamine and varied lauroyl-CoA.

Figure A.9 Bm-AANAT with 60 mM tryptamine and varied myristoyl-CoA.
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Figure A.10 Bm-AANAT with 60 mM tryptamine and varied oleoyl-CoA.

Figure A.11 Bm-AANAT with 60 mM tryptamine and varied palmitoyl-CoA.
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Figure A.12 Bm-AANAT3 with 500 μM acetyl-CoA and varied dopamine.

Figure A.13 Bm-AANAT3 with 500 μM acetyl-CoA and varied histamine.
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Figure A.14 Bm-AANAT3 with 500 μM acetyl-CoA and varied norepinephrine.

Figure A.15 Bm-AANAT3 with 500 μM acetyl-CoA and varied octopamine.
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Figure A.16 Bm-AANAT3 with 500 μM acetyl-CoA and varied serotonin.

Figure A.17 Bm-AANAT3 with 500 μM acetyl-CoA and varied tryptamine.
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Figure A.18 Bm-AANAT3 with 500 μM acetyl-CoA and varied tyramine.

Figure A.19 Bm-AANAT3 with 8 mM tryptamine and varied acetyl-CoA.
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Figure A.20 Bm-AANAT3 with 8 mM tryptamine and varied butyryl-CoA.

Figure A.21 Bm-AANAT3 with 8 mM tryptamine and varied hexanoyl-CoA.
123

Figure A.22 Bm-AANAT3 with 8 mM tryptamine and varied octanoyl-CoA.

Figure A.23 Bm-AANAT3 with 8 mM tryptamine and varied decanoyl-CoA.
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Figure A.24 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 6.5)

Figure A.25 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 7.0)
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Figure A.26 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 7.5)

Figure A.27 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 8.0)
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Figure A.28 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 8.5)

Figure A.29 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 9.0)
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Figure A.30 Bm-AANAT3 pH-rate profile with varied acetyl-CoA (pH = 9.5)

Figure A.31 Bm-AANAT3 double reciprocal plot with varied tryptamine at constant
concentrations of acetyl-CoA. For data sets fit to global nonlinear regression analysis, see
Figures 2.3A.
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Figure A.32 Bm-AANAT3 double reciprocal plot with varied acetyl-CoA at constant
concentrations of tryptamine. For data sets fit to global nonlinear regression analysis, see
Figures 2.3B.

Figure A.33 Bm-AANAT3 E27A site-directed mutant with varied acetyl-CoA.
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Figure A.34 Bm-AANAT3 E27A site-directed mutant with varied tryptamine.
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Figure A.35 Bm-AANAT product characterization with LC/QTOF-MS. Resulting Noleoyltryptamine from the Bm-AANAT-catalyzed reaction in vitro.
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Figure A.36 Bm-AANAT product characterization with LC/QTOF-MS. Synthesized Noleoyltryptamine standard.
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Figure A.37 Bm-AANAT product characterization with LC/QTOF-MS. No enzyme blank.
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Bm-AANAT codon-optimized gene sequence:
CATATGGCAGTCACCAGCACCCGTGGCATTGTCAACCTGAAAGAAAAAGGTCACTT
CGAACGCGAAAACGCTCGTGTGGAAAAATATACCCTGGGCGATGAACTGCCGGCTC
AGCTGAGCTCTCTGGAAATTCGTCCGCGCAAAATGAGCGTGCCGGCGTATACCATCC
AACGTCTGACGTACAACGATCGCGACCTGGTTCTGAAATTCCTGCGTCGCTTTTTCTT
TCGTGACGAACCGATGAACCTGGCCGTTAATCTGCTGGAAACCCCGGAATCTCGCTG
CACGGAACTGGATGACTATGCGGCCGCAACCCTGAGCGATGGCGTGTCTGTTGCTGC
GGTCGATGAAAACGGCGACTATGTCGGTGTGATTATCAATGGTATTGTTCGTCGCGA
AGAAGTCGATTACACCGACAAAAGCGAAGATTGTCCGAATCCGAAATTTCGTCGCA
TTCTGAAAGTGCTGGGCCATCTGGATCGTGAAGCCCGCATCTGGGACAAACTGCCGG
AAACCTGCGATAGTGTCCTGGAAATTCGTATCGCATCCACCCACAGTTCCTGGCGTG
GTCGCGGTCTGATGCGTGTGCTGTGTGAAGAAGCTGAACGCCTGGCCAAAGCAATG
GGTGCTGGTGCCCTGCGTATGGACACCACGTCAGCATTCTCGGCCGCAGCTGCGGAA
CGTCTGAACTATAAAATGGCCTTTGGTGTTCGCTACGCAGATCTGCCGTACGCCCCG
CAACCGGAAGCCCCGCACCTGGAAGCCCGTGTCTACATCAAAGAACTGTGACTCGA
G

Bm-AANAT3 codon-optimized gene sequence:

CATATGGCTGATTTTGTTGTTGTGATGCCGTCAATGAAAGATGCCGTTATCCAGCAC
CTGCGTGATTCCTTCTTTGCCGATGAACCGCTGAACAAAGCCGTGGGTCTGTGTGAA
CGTGGTCAGCCGCATGCCGCACTGGAACGTCTGTGTCTGGCAACCATGACGGATGG
CCTGTCCATTGCAGCTATGGATGGCGACAAAGTGCTGGGTGTTGCACTGAATGGCAT
TCTGCGTCACGGTGATATCGAACAGAGTATCGAAAAAATCAAACAATCCACCGACG
AAAAATTCAACAAAATCTTCAACATCCTGTATACCGTTAGCCGTGATCTGAACCTGT
TTAATACGTTCGAAGTCGACCTGATCATGGAATGCCGCATTATCAGCGTGCATGAAA
ACGCACGTGGCCGCGGTCTGGCTAAAGAACTGATGAAACGTTCTATTGATCTGGCGC
GCGACAACGAATTTAAACTGTTCAAAGTTGATGCGACCGGCGCCTTTAGTCAACGTA
TCTGCCGCAGCCTGTCTCTGGAAGAACTGAAATCAGTCCGCTATGATGAATACTGTG
ACGAATCGGGTACGCCGATCTTCCGTGTGCCGCCGCCGGACCATGCCCTGTGTGTTA
TGATTCTGAAACTGCCGTAACTCGAG
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APPENDIX B
Chapter 3 Supplementary Information

Figure B.1 Compound 2 proton NMR
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Figure B.2 Compound 3 proton NMR
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Figure B.3 Compound 4 proton NMR
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Figure B.4 Compound 6 proton NMR
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Figure B.5 Compound (Probe) 7 proton NMR
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APPENDIX C
Chapter 4 Supplementary Information

Figure C.1 Plasmodium vivax DXS steady-state kinetic constants with varied Pyruvate.
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Figure C.2 Plasmodium vivax DXS steady-state kinetic constants with varied GAP.

Figure C.3 Plasmodium facliparum DXS steady-state kinetic constants with varied Pyruvate.
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Figure C.4 Plasmodium facliparum DXS steady-state kinetic constants with varied GAP

Plasmodium vivax (Sal-1) DXS SH-2 variant (Truncated & codon-optimized):

TATCCGACCTCCGCGACGCTGGGCAAAAAACTGTTCAACGTGAAAAACGAAGAAGG
TCAAACCGGCCGCGAACCGCAACTGTCTGGTGCGAACGAAAAAAGTGATGACAACC
GTGATCCGCCGAATCTGGATGCCCTGTTCGACCAGATCAACTCATACATCGATGTTG
AAAAATACCGCGACACCTACGGCGAAGAAATCTACCATAAAATGGTGAAACTGTAC
GTTCGTCGCGATGTCCCGGAAAACTATGAAGAACTGTTTTTCACCGAACCGACGGAA
AAATCGGTGGCCCTGGATGTTGACAAATACGATGAAGACCACTTTGAAAAACTGAT
GCGTGAAGAATTCCAGCGCAACGGTGTGCTGATCAAAAACATCAGTAAAGAATACT
ACCAAAAAGAAAACATCAAAAAAGTGCTGAAAGTTCTGAAATACCTGCCGCTGCTG
CGTCTGATCAACAATCCGTCCGATCTGAAAAAACTGAAAAAAGAATGCCTGCCGCT
GCTGGCACATGAACTGAAAATGTTCCTGTTTTTCATGGTGAACATCACCGGTGGCCA
CTTTTCCGCTGGCCTGTCACTGCTGGAAGTTCAGCTGCTGCTGCTGTACCTGTTTGAT
CATCCGCACGATGACGTTATTTATGACATCGGTCATCAAGCGTACGTCCACAAAATT
CTGACCGGCCGCAAACTGCTGTTCCTGAGTCTGCGTCGCAAAAAAGGTATTTGTGGC
TTTCTGAATATCTTCGAAAGCGCCTATGATAAATTTGGTGCAGGCCATAGTTCCACC
GCTCTGTCTGCGATTCAGGGTTTCTACGAAGCCGATTGGCAGGTTTGGCAATTTTGG
CGTAAACGCACCGCTCATCCGGAAGAACGTCTGACCACGTCAAGCGCCCATCCGGG
TGAAGAAGGCCCGACCCGTGCTGGCGAAAACCAGCAAGCGAGCCATCCGAATCGCG
GTGGCACCACGCAGCAATCAGCCTATCCGGGTCGTAACAATTCGGCAGATCATCTG
AACAAAGTGCACATTGCCATTATTGGTGATGGTGGTCTGACCGGTGGCATGGCCCTG
142

GAAGCACTGAACTATATCTCGTTTCTGAATAGCAAAGTGCTGATTATCTACAACGAT
AATGGTCAGGTTTCTCTGCCGACGAATGCACCGTCGATTAGCGGTCATCGCCCGATT
GGCTCTATCAGTGATCATCTGCACTCCTTCCTGGCCCGTAAAAGCGGTAAAGGCGAA
TCTCAGCAAGCAAGTGGCACCAAGAAAAACAACATCTTCGAAAACCTGAACTACGA
TTACGTCCAGGTGCAAAACGGTAATGACACCGAAGCGCTGTTTAACGCTCTGAGCGC
GTTCAAAAAAGGCAAAATGAATCGCGCCACGGTCCTGCATGTGTGCACCTCGAAAA
CGAGCGATTTTATTAACGCGCGTGCCCCGATCACCGTTATGCATTCAATTAAGAAAA
ACGAAATCTTCCCGTTCTCCGAAGATGCTCTGTCACCGCACGGTAAAGAAGGCGAAT
CGGCGGGTCATACGGCACACGCTCAGGATGACCAAGCCAACCGCGGCAAATCAAAT
TTCGCTAAAGAACAGCAAGAAGATGCGAAAATTTTTAGCAAAGAAACCTTCACGGA
CGTGTTCACCGAAGAAATGCTGACGTACCTGGAACGTGATAAAAACGTTATCTTCAT
CAGTCCGGCCATGCTGGGTGGCAGCGGTCTGGTCAAAATTAGCGAAAAATATCCGG
ATAACGTTTACGACGTCGGCATCGCCGAACAGCATGCAGTTACCTTCGCGACGGCCA
TGGCAATGAACAAAAGCCTGAAAATCTACCTGTGTATCTACTCTACCTTCATGCAGC
GCGCGTATGATCAAATTATCCATGACCTGAACCTGCAGAAAGTGCCGCTGAAAGTTA
TTGTCGGTCGTTCCGGCCTGATCGGTGAAGATGGCGCGACCCACCAGGGTATTTACG
ACCTGACGTTCCTGGGCGCTCTGAACAATGCGTGCGTTATCTCCCCGTCAAATCAGG
TCGATCTGAAAAAAGCGCTGAAATTTTGTCATCACGACGTGAACCGCCCGGTGTTTG
TTCGTCTGCCGCGCATTAATACCTTCACGGAAGAATATCTGCGTGGTTACTTTCGTAT
CGGTGGCGGTGGCCAGGTTGGTTGGGAAGAAAGCAAAACCGGCGAAGATCCGCTGA
AAGAAGAACTGCAAACGTTTTTCGGTAAAGCGCGTGTGATTAAAATCAGTCCGGAA
GAGAAAAAACCGAACGAAGGCGGCAAGAAAAAAGTTGCCATTTTTAATATGGGCTC
CATGCTGTTCAACGTGCTGAATGCCATTGAAGCAATCGAAAAAGATCATCTGCTGGC
GTCTCGCTTTAGTTTCACCGTGGTTGACATGATTTTTCTGAACCCGATGGATAGCTCT
ATTGTCGACTATCTGATTGTGCGTAACAAACATGATGTGCACATCACCTACGAAGAC
AATACGGTTGGTGGCTTTTCTACCCACTTCAACAACTACCTGATCGGCAAAAACTAC
ATCTCGCGCCATCAGCTGAGCGTGCACAACATTTATCTGCCGAATGATCCGATCGAA
CATGCTACCTACGCGGAACAGCACGTCGATGTGAAAATGGACAGTTCCTCACTGGA
AAATCGCATCCGCTCCTTTCTGCAGGGTGGTGTTAGCAAC

Plasmodium vivax (Sal-1) DXR (codon-optimized):

ATGAAAGGGTCCATTTGTTTGCACACCCTGTTGTTGCTCGTCGGCATGCAGGAAATG
GGGGCCGGTCGTGTGTGCCCCCAACGTGGTGAGAGGAAAAGGGCGTACGTAATAAA
TATGAAACGGGGGAGCGTGCAGAATGGTGGAGCGAGGCGAGGGCTGTGGTCCGGG
CGGGTAAAGTTTAGGAAGCGGGAGGACCTCTCCCGTGGGGGCAGAGGCCCTGAGTG
CGCGGTGAACGCGGTGAACGCGGCCAGCGCGGCAAATAATGGCAACCCCGCTAACG
CCGCTAACGATGCTAACGCTTCTAACCCCTCTAACCGCGCTAACCGCGCTAACCCCG
CCAACTGCATCAACGTGGCCATCTTCGGGAGCAGCGGGAGCATCGGCGCGAACGCG
CTGGACGTGATTCGCGAGTGCAACCGAGTTGAGAGGCGCTTCAACGTGGAGGCCCT
GTACGTCAACAAAAGCGTGACCAAACTGTATGAACAGGCAAGGGAGTTTTTGCCAA
AGTATGTGTGCATCCACGATGAGTCAAAATATGAGGAATTAAAAATGTTGTTAAGA
AAAATAAAGGGATACAACCCAGAGATACTAGTGGGGGATGATGGCATGAAACAAA
TGTGCAGCAGCAACACACTAGACAGAATTATAATTGGGATCGACTCCTTCCATGGGT
143

TATACTCAACCATATATGCAATTAAAAGCAATAAAATTATTGGGCTAGCGAATAAA
GAGTCAATCGTATCTGCAGGATTTTTTCTCAAAAAATTATTAACAAGTCATACAAAA
TCGTGCATTATTCCAGTGGACTCAGAACACAGTGCCATCTTCCAATGTTTGGATAAT
AACAAAGTTTTAAAAACGAAATGTCTGCAGGATAGCTTCTCCAAAGTGAATCAAAT
AAAAAAATTAATTTTATCCTCCTCAGGTGGCCCCTTTCAAAATGCCTCCCTTGATGA
GCTGAAAAAAGTAACCGCAGAAGATGCCCTCAAACATCCAAAGTGGAAAATGGGAC
CCAAAATAACCATCGACTCTGCAACTATGATGAACAAAGGGTTAGAGGTGATTGAG
GCTCATTTCCTCTTCGACGTAGATTACAATCATATAGAAATCCTTGTGCATAAGGAA
TGTATTCTCCATTCGTGCGTAGAATTTATAGACAAATCGGTTGTAAGCCAAATGTAC
CTCCCAGATATGAAGCTTCCAATTCTATATGCTTTGACTTGGCCTAATAGAATTGCTA
CAGAATTGCCGTCTCTTAATTTGGCTAGTACGTCTCCCCTTACATTTTACTCCCCCTC
ACTGGACCACTTCCCTTGTATCAAGCTGGCGTACCAGGCAGGTCGGCAGGGGAACTT
CTACCCAACTGTCCTCAACGCGGCCAACGAGGTGGCCAACAAACTATTTCTAAGTAA
CAAAATTGGCTACTTTGACATTGCCGCCATCATATCTGACGTTTTGGAGTCCTTCACG
CCGCAGGAGGTCTCCAACAACTGCGAGGATTTGATGCACCAAATTGGGGGCATCCA
CAAGTGGGCCGTCCGCAGGGCTGAGGAGGTGTACCGGGTGCGCTCCTCCGCAGCGC
AGTGA

Plasmodium falciparum (3D7) DXS (codon-optimized):

ATGATTTTTAATTATGTGTTTTTTAAGAACTTTGTACCAGTTGTTCTATACATTCTCCT
TATAATATATATTAACTTAAATGGCATGAATAATAAAAATCAAATAAAAACAGAAA
AAATTTATATAAAGAAATTGAATAGGTTGTCAAGGAAAAATTCGTTATGTAGTTCTA
AAAATAAAATAGCATGCTTGTTCGATATAGGAAATGATGATAATAGAAATACGACA
TATGGCTATAATGTGAATGTTAAAAATGATGATATTAATTCCTTACTAAAAAATAAT
TATAGTAATAAATTGTACATGGATAAGAGGAAAAATATTAATAATGTAATTAGTACT
AATAAAATATCTGGGTCCATTTCAAATATTTGTAGTAGAAATCAAAAAGAAAATGA
ACAAAAAAGAAATAAACAAAGATGTTTAACTCAATGTCACACTTATAATATGTCAC
ATGAACAGGACAAACTAGCTAATGATAATAATAGGAATAATAAAAAGAATTTTAAT
TTATTATTTATAAATTATTTTAATTTGAAACGAATGAAAAATTCTCTTCTAAATAAAG
ACAATTTCTTTTACTGTAAAGAAAAAAAATTGTCATTTCTGCATAAGGCCTATAAAA
AAAAAAATTGCACTTTTCAAAATTATAGTTTAAAAAGAAAATCTAATCGTGATTCAC
ATAAATTGTTTTCTGGAGAATTTGACGATTATACAAATAATAATGCTTTATATGAAT
CCGAAAAAAAAGAATACATTACACTAAATAATAATAATAAAAATAATAATAATAAA
AATAATGATAATAAAAATAATGATAATAATGATTATAATAATAATAATAGTTGTAAT
AATTTAGGAGAGAGATCCAATCATTATGATAATTATGGTGGAGATAATAATAATCCA
TGTAATAATAATAATGACAAATATGATATAGGAAAATATTTCAAACAGATTAATACC
TTTATTAATATTGATGAATATAAAACTATATATGGTGATGAAATATATAAAGAAATA
TATGAACTATATGTAGAAAGAAATATTCCTGAATATTATGAACGAAAATATTTTTCA
GAAGATATTAAAAAGAGTGTCCTATTTGATATAGATAAATATAATGATGTCGAATTT
144

GAAAAAGCTATAAAAGAAGAATTTATAAATAATGGAGTTTATATTAATAATATAGA
TAATACATATTATAAAAAAGAAAATATTTTAATAATGAAAAAGATATTACATTATTT
CCCATTATTAAAATTAATTAATAATCCATCAGATTTAAAAAAGTTAAAAAAACAATA
TTTACCTTTATTAGCACATGAATTAAAAATATTTTTATTTTTTATTGTAAATATAACA
GGAGGTCATTTTTCCTCTGTTTTAAGCTCTTTAGAAATTCAATTATTATTATTGTATAT
TTTTAATCAACCATATGATAATGTTATATATGATATAGGACATCAAGCATATGTACA
TAAGATATTGACCGGAAGAAAACTATTATTTCTATCATTAAGAAATAAAAAAGGTAT
TAGTGGATTCCTAAATATTTTTGAAAGTATTTATGATAAATTTGGGGCTGGTCACAG
TTCCACTTCATTAAGTGCTATACAAGGATATTATGAAGCCGAGTGGCAAGTGAAGAA
TAAAGAAAAATATGGAAATGGAGATATAGAAATAAGTGATAACGCAAATGTCACGA
ATAATGAAAGGATATTTCAAAAAGGAATACACAATGATAATAATATTAACAATAAT
ATTAATAATAATAATTATATCAATCCTTCAGATGTGGTAGGAAGAGAAAATACGAAT
GTACCAAATGTACGAAATGATAACCATAACGTGGATAAAGTACACATTGCTATTATA
GGAGATGGTGGTTTAACAGGTGGAATGGCATTAGAAGCGTTAAATTATATTTCATTC
TTGAATTCTAAAATTTTAATTATTTATAATGATAACGGACAAGTTTCTTTACCAACAA
ATGCCGTAAGTATATCAGGTAATAGACCTATAGGTTCTATATCAGATCATTTACATT
ATTTTGTTTCTAATATAGAAGCAAATGCTGGTGATAATAAATTATCGAAAAATGCAA
AAGAGAATAACATTTTTGAAAATTTGAATTATGATTATATTGGTGTTGTGAATGGTA
ATAATACAGAAGAGCTCTTTAAAGTATTAAATAATATAAAAGAAAATAAATTAAAA
AGAGCTACTGTTCTTCATGTACGTACAAAAAAATCGAATGATTTTATAAATTCAAAG
AGTCCAATAAGTATATTGCACTCTATAAAGAAAAATGAGATTTTCCCTTTCGATACC
ACTATATTAAATGGAAATATTCATAAGGAGAACAAGATAGAAGAAGAGAAAAATGT
GTCTTCATCTACAAAGTATGATGTAAATAATAAGAATAATAAAAATAATGATAATA
GTGAAATTATAAAATATGAAGATATGTTTTCAAAAGAGACGTTCACAGATATATATA
CAAATGAAATGTTAAAATATTTAAAGAAAGATAGAAATATAATATTCCTATCTCCCG
CTATGTTAGGAGGATCAGGATTGGTTAAAATTAGTGAGCGTTATCCAAATAATGTAT
ATGATGTAGGTATAGCAGAACAACATTCTGTAACTTTCGCAGCAGCTATGGCAATGA
ATAAGAAATTAAAAATACAATTATGTATATATTCGACCTTTTTACAAAGAGCATATG
ATCAAATTATACATGATCTTAATTTACAAAATATACCTTTAAAGGTTATAATTGGAA
GAAGTGGATTAGTAGGAGAGGATGGGGCAACACATCAAGGTATATATGATTTATCT
TATCTTGGGACACTTAACAATGCATATATAATATCTCCAAGTAATCAAGTTGATTTG
AAAAGAGCTCTTAGGTTTGCTTATTTAGATAAGGACCATTCTGTGTATATACGTATA
CCCAGAATGAACATATTAAGTGATAAGTACATGAAAGGATATTTGAACATTCATATG
AAAAATGAGAGCAAAAATATCGATGTAAACGTGGATATAAACGATGATGTAGATAA
ATATAGTGAAGAATATATGGACGATGATAATTTTATAAAATCGTTTATTGGAAAATC
TAGAATTATTAAAATGGATAATGAAAATAATAATACAAATGAACATTATTCAAGCA
GAGGAGATACACAGACAAAAAAAAAAAAAGTTTGTATCTTTAACATGGGTAGTATG
CTTTTTAATGTAATTAATGCTATAAAAGAAATTGAAAAAGAACAATATATTTCACAT
AATTATTCTTTTTCAATTGTTGATATGATATTTTTAAATCCTTTAGATAAAAATATGA
TAGATCATGTAATAAAACAAAATAAACATCAATATTTAATTACTTATGAAGATAATA
CTATAGGTGGTTTTTCTACACATTTCAATAATTATTTAATAGAAAATAATTATATAAC
AAAACATAATTTATATGTTCATAATATTTATTTATCTAATGAGCCAATTGAACATGC
ATCTTTTAAGGATCAACAAGAAGTTGTCAAAATGGATAAATGTAGTCTTGTCAATAG
AATTAAAAATTATCTTAAAAATAATCCTACATGA
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Plasmodium falciparum (3D7) DXR (codon-optimized):

ATGAAGAAATATATTTATATATATTTTTTCTTCATCACAATAACTATTAATGATTTAG
TAATAAATAATACATCAAAATGTGTTTCCATTGAAAGAAGAAAAAATAACGCATAT
ATAAATTATGGTATAGGATATAATGGACCAGATAATAAAATAACAAAGAGTAGAAG
ATGTAAAAGAATAAAGTTATGCAAAAAGGATTTAATAGATATTGGTGCAATAAAGA
AACCAATTAATGTAGCAATTTTTGGAAGTACTGGTAGTATAGGTACGAATGCTTTAA
ATATAATAAGGGAGTGTAATAAAATTGAAAATGTTTTTAATGTTAAAGCATTGTATG
TGAATAAGAGTGTGAATGAATTATATGAACAAGCTAGAGAATTTTTACCAGAATATT
TGTGTATACATGATAAAAGTGTATATGAAGAATTAAAAGAATTGGTAAAAAATATA
AAAGATTATAAACCTATAATATTGTGTGGTGATGAAGGGATGAAAGAAATATGTAG
TAGTAATAGTATAGATAAAATAGTTATTGGTATTGATTCTTTTCAAGGATTATATTCT
ACTATGTATGCAATTATGAATAATAAAATAGTTGCGTTAGCTAATAAAGAATCCATT
GTCTCTGCTGGTTTCTTTTTAAAGAAATTATTAAATATTCATAAAAATGCAAAGATA
ATACCTGTTGATTCAGAACATAGTGCTATATTTCAATGTTTAGATAATAATAAGGTA
TTAAAAACAAAATGTTTACAAGACAATTTTTCTAAAATTAACAATATAAATAAAATA
TTTTTATGTTCATCTGGAGGTCCATTTCAAAATTTAACTATGGACGAATTAAAAAAT
GTAACATCAGAAAATGCTTTAAAGCATCCTAAATGGAAAATGGGTAAGAAAATAAC
TATAGATTCTGCAACTATGATGAATAAAGGTTTAGAGGTTATAGAAACCCATTTTTT
ATTTGATGTAGATTATAATGATATAGAAGTTATAGTACATAAAGAATGCATTATACA
TTCTTGTGTTGAATTTATAGACAAATCAGTAATAAGTCAAATGTATTATCCAGATAT
GCAAATACCCATATTATATTCTTTAACATGGCCTGATAGAATAAAAACAAATTTAAA
ACCTTTAGATTTGGCTCAGGTTTCAACTCTTACATTTCATAAACCTTCTTTAGAACAT
TTCCCGTGTATTAAATTAGCTTATCAAGCAGGTATAAAAGGAAACTTTTATCCAACT
GTACTAAATGCGTCAAATGAAATAGCTAACAACTTATTTTTGAATAATAAAATTAAA
TATTTTGATATTTCCTCTATAATATCGCAAGTTCTTGAATCTTTCAATTCTCAAAAGG
TTTCGGAAAATAGTGAAGATTTAATGAAGCAAATTCTACAAATACATTCCTGGGCCA
AAGATAAAGCTACCGATATATACAACAAACATAATTCTTCATAG

.
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